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ABSTRACT
Bypassing the Blood-Brain Barrier: A Physical and Pharmacological
Approach for the Treatment of Metastatic Brain Tumors
Samuel A. Sprowls

This dissertation (a) provided an in depth literature review of methods to disrupt the
BBB/BTB and improve therapeutic distribution to brain tumors, (b) evaluated the use of
azacitidine as a single agent therapy for the treatment of brain metastasis of breast
cancer and a potential molecular mechanism by which brain tropic cells are sensitized to
hypomethylating agents, (c) determined the impact cannabidiol has on P-glycoprotein
mediated efflux at the blood-brain barrier and its potential for use as a single agent
treatment for metastatic brain tumors, (d) developed a preclinical radiation therapy
protocol for use in small animals and in vitro systems, (e) evaluated the impact radiation
therapy has on blood-brain barrier integrity in normal and pathological brain, and (f)
provided a discussion on the mathematical models used to evaluate blood-brain barrier
pharmacokinetics in both normal and pathophysiological conditions.
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Chapter 1
Introduction
The blood-brain barrier (BBB) is a dynamic, physiochemical barrier at the
interface between the systemic circulation and the brain. In health, the BBB acts
as a mechanism for neuroprotection, nutrient exchange, and maintenance of
cerebral blood flow among other various functions. In many disease states, such
as ischemic stroke, Alzheimer’s, systemic lupus, cancer, etc., the BBB can be
disrupted, or “leaky”.

In metastatic brain tumors, the BBB, or the blood-tumor barrier (BTB), is
heterogeneously disrupted. The foundational work from our lab described that
while the BTB is leaky, a majority of brain lesions never reach cytotoxic
concentrations of the various chemotherapies in a preclinical model of breast
cancer brain metastases. Because of the BTB, most chemotherapeutics are near
useless for brain tumors, partially due to either increased active efflux or poor
drug permeation.

Cancer metastasis is defined as the spread of a primary cancer, i.e. breast
cancer, lung cancer, or melanoma, to a secondary site, such as the lungs or
brain. Metastasis to the brain is estimated to occur in up to 10% of all cancer.
Specifically, for breast cancer patients, up to 30% of the women unfortunately
diagnosed with primary breast cancer are at risk for development of brain
1

metastases. Survival for these women is poor and most patients typically survive
less than two years from central nervous system disease onset. Treatment
options are few, and mostly palliative, for brain tumors. These modalities include
radiation therapy, either whole-brain radiotherapy or stereotactic radiosurgery,
surgical resection, and/or systemic chemotherapy. As mentioned, these options
are not curative, but serve to provide the hopes of a few more months of life.

For the aforementioned details and various other possible neurological
complications, novel treatment strategies to manage breast cancer brain
metastases are crucial. In the past few decades, novel chemotherapeutics,
redesigned drug formulations, and alternate routes of drug administration have
provided hope, but have failed to provide modest survival benefits. In this
dissertation, we investigate the use of an FDA approved hypomethylating agent
in the treatment of breast cancer brain metastasis (BCBM). Additionally, we
describe the ability of cannabidiol to inhibit P-glycoprotein mediated efflux at the
BBB and evaluate the efficacy of combinatorial therapy utilizing cannabidiol in
our preclinical model of BCBM. Lastly, we describe the effects of radiation
therapy on the BBB and the BTB, regarding the time frame of disruption posttherapy and the impact said disruption may have on chemotherapy permeability.

Chapter 2 provides an in-depth review of the BBB, brain metastases, active efflux
at the BBB, and novel treatment modalities used to physically disrupt the BBB for
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increased chemotherapeutic efficacy when treating brain tumors. Clinical trials
utilizing these techniques are also discussed herein.

Chapter 3 details the use of azacitidine, an approved hypomethylating agent, in
the treatment of brain metastases of breast cancer. In this chapter the potential
mechanism of action of azacitidine is also explored in vitro.

Chapter 4 investigates the use of cannabidiol for increased drug distribution to
brain through inhibition of P-glycoprotein efflux, as well as its efficacy in both the
prevention and treatment of BCBM.

Chapter 5 describes the effect of development of a small animal radiation
research platform using a host of dosimetry techniques. Additionally, this model
was used to evaluate the effects of radiation therapy on the BBB and the BTB in
vivo regarding permeability of the fluorescent tracer, Texas Red. A comparison of
literature reported experiments involving radiation and the BBB or BTB is
provided.

Chapter 7 reviews the classical pharmacokinetics regarding solute uptake at the
BBB. Mathematics for determining the rate at which a compound is effluxed from
the brain, Kout, are also described. When applied to disease models these
mathematics provide quantitative measurements of drug or tracer uptake and
provide more analytical data than those reported in fold-change. These
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mathematics will provide a framework for future work investigating tracer uptake
following radiation.

In summary, this dissertation provides a detailed discussion of the blood-brain
and blood-tumor barriers, and describes both physical and pharmacological
means to treat BCBM. When viewed together, these data highlight various
means to bypass brain barriers through rational drug design, active efflux
inhibition, and physical disruption. Additionally, a preclinical model for radiation
research was also established at our university. Lastly, this dissertation provides
a mathematical approach for quantification of solute uptake in normal and
compromised brain. No matter the experiment, the main goal of the work herein
was to improve upon the use of currently available treatments to provide even
modest survival benefits for those suffering from BCBM.
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Chapter 2
Improving CNS delivery to brain metastases by Blood Tumor
Barrier disruption.

2.1 Brain Metastases and Treatment Failure
Brain metastasis is an overwhelming morbidity of late stage cancer progression.
Central nervous system (CNS) metastases occur in approximately 10% of all
cancer types [1]. Recent increases in brain metastases are thought to be caused
by improved control of systemic disease and increasingly sensitive imaging
modalities [2]. Patients with CNS disease typically succumb within two years of
diagnosis [3-5]. Therapies for brain lesions are mostly palliative, and rarely ever
curative. These therapies include bulk surgical resection of the tumor(s),
radiation therapy (either whole-brain and/or stereotactic), and/or systemic
chemotherapy [6]. The blood-brain barrier (BBB), the brain’s innate defense
system against blood delivered harmful substances, prevents delivery of most all
efficacious systemic chemotherapies into brain tissue [7].

2.2 The Blood-brain Barrier
The BBB’s unique properties occur as a result of specific interactions between
endothelial cells, pericytes, astrocytes, microglia and neurons, and their
molecular components as seen in Figs. 2.1, 2.3a [8]. Proper regulation and
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function of the BBB is dependent on uninhibited interaction and communication
between these cells.

Endothelial Cells
Brain microvascular endothelial cells (EC) form the foundation layer of the BBB
and are crucial to the maintenance of its integrity. The ECs of the BBB are
polarized in structure, as their luminal and abluminal surfaces have diverse
biochemical and functional features; e.g. increased luminal γ-glutamyl
transpeptidase expression [9]. The specialized BBB ECs have a high degree of
expression of various transporters, including P-glycoprotein (P-gp, ABCB1),
breast cancer resistance protein (BCRP, ABCG2), multi drug resistance protein,
and various nutrient transporters [9]. These transporters move nutrients into the
brain and efflux waste and other molecules out of the brain. Efflux pump
expression is a major obstacle in overcoming drug delivery to the brain.
One of the most crucial features of ECs is their expression of tight junctions (TJ),
which stabilizes the integrity of the BBB. The expression of TJ’s is induced by
pericytes and results in a non-fenestrated vasculature preventing any unwanted
“leaking” of luminal contents into the parenchyma of the brain. The TJ proteins
are comprised of various transmembrane proteins including claudins, occludins,
junctional adhesion molecules and accessory proteins, such ZO-1 and ZO-2 [10].
Another important trafficking molecule in normal BBB anatomy is major facilitator
superfamily domain 2a (Mfsd2a). This protein is important for development of a
functional BBB and is required for movement of docosahexaenoic acid into brain
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tissues [11, 12]. Importance of this transporter in BBB integrity and functionality is
demonstrated by mice with genetically removed Mfsd2a that have decreased
docosahexaenoic acid transport and increased disruption of the vascular barrier
in brain [13].

Pericytes
Pericytes share the basement membrane with ECs and attach to them by ‘pegsocket’ junctions within the cerebral vasculature [14, 15]. During developmental
stages and adult life, pericytes are recruited to EC of the BBB through several
signaling methods, primarily the platelet derived growth factor-β pathway [14].

The presence of pericytes is critical for proper BBB function and development.
These accessory cells directly influence permeability of the BBB by inducing EC
TJ formation [16]. Next, pericytes regulate cerebral blood flow and waste
clearance, disruption of which is associated with multiple brain pathologies, such
as Alzheimer’s [15, 16]. Pericytes are shown to polarize astrocytic end-foot
processes surrounding the BBB, and further are shown to regulate EC gene
expression, increasing their viability through the Bcl2l2 pathway [17, 18].

Astrocytes
Astrocytic end-feet processes surround the BBB almost entirely. Their end-feet
connect to the basement membrane through junctional molecules, including
dystroglycan as well as channels like aquaporin 4, a molecule shown to maintain
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water homeostasis in the brain [10, 19]. Astrocytes play several roles in the
regulation of the BBB. They assist in regulation of cerebral blood flow through
Ca2+ signaling following neuronal perturbation [20]. Further, astrocytes are
responsible for maintenance and formation of EC TJ. Sonic hedgehog, ang-1,
and transforming growth factor signaling pathways influence this maintenance
[10, 21]. Lastly, astrocytes directly impact vascular growth and proliferation
through ang-1 and vascular endothelial growth factor (VEGF) secretion [10, 22,
23].

Microglia
Microglia are the resident immune cells of the brain. These cells play a role in
both pro- and anti-inflammatory responses. Depending on their pro-inflammatory
(M1) or anti-inflammatory (M2) phenotypes, they control inflammation through
release of various molecular cytokines. Microglia are involved in angiogenesis,
especially near EC tip cells, suggesting their influence in cerebral vascular
development [24, 25]. However their role in maintenance of the integrity of a
healthy BBB is still unknown.

2.3 The Blood-tumor Barrier
Of the primary cancers that migrate to the brain, lung, breast, melanoma, and
renal cancers comprise the majority of metastatic brain tumors affecting ~50%,
~15%, ~10%, and ~5% of patients respectively [2]. Brain metastasis occurs when
a circulating tumor cell, of a primary systemic tumor (i.e., breast, lung,
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melanoma, renal), detaches from the initial tumor mass and arrests in the brain
microvascular capillary network, extravasates through the vessel wall into the
perivascular space, and survives and proliferates into a new lesion [26, 27]. From
initial metastatic colonization, the newly “seeded” brain metastatic tumor cells coopt the brain vasculature eliciting neo-angiogenesis and microenvironment
remodeling to promote tumor growth and further invasion. The newly formed
neurovascular-tumor unit is termed the blood-tumor barrier (BTB, Fig. 2.2) and
has differential properties concerning therapy pharmacokinetics and action in
comparison to the intact BBB.

The BTB is inherently “leaky”, lacking tight junctions and astrocytic-endothelial
contacts resulting in significant heterogeneous permeability from lesion to lesion
within the brain [28, 29]. As lesions continue to outgrow their oxygen supply,
angiogenesis occurs driven largely by VEGF. These new vessels are inherently
leaky compared to the BBB phenotype. Dynamic angiogenesis during metastatic
progression is different among brain lesions, which is thought to contribute to the
heterogeneity in tumor permeability to chemotherapy. Additional contributions to
increased permeability of the BTB include the lack of physiological TJ protein
expression causing fenestra and discontinuous endothelia [28, 30].
Inconsistencies of junctional protein expression can allow for the passive
permeability of cytotoxic therapies into tumor tissue. Interestingly mfsd2a is
down-regulated at the BTB and promotes brain metastatic outgrowth due to lack
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of astrocytes promoting endothelial expression of mfsd2a, further contributing to
BBB leakage in brain tumors [31].

Efflux mediated by P-gp (ABCB1) and BCRP (ABCG2) at the BBB limits
distribution to normal brain of most chemotherapeutic agents. In the BTB setting,
P-gp and BCRP have been found to be increased at the luminal membrane, as
well as in the plasma membrane of tumor cells [32-34]. In preclinical mouse
models, Elmquist and colleagues have demonstrated the active efflux of a host of
agents used to treat melanoma and lung cancer brain metastases [32, 35, 36].

Other cellular and molecular properties of the BTB are prompted by astrocytes,
pericytes and microglia. Astrocytes function to support and protect neuronal cells
from damage and apoptosis through secretion of inflammatory cytokines such as
TNFα, IL1, and IL6. Release of these cytokines encourages tumor proliferation
and survival.[37] Additionally, astrocytes release exosomes containing miRNA19a, which serves to induce loss of PTEN and promote further outgrowth and
invasion of tumor cells within the brain [37, 38]. Microglia in the brain tumor
microenvironment are known to secrete multiple growth factors and cytokines,
such as TGFβ, TNFα, IL1, IL6, VEGF, EGF, and many metalloproteinases [39].
The molecular entities secreted by microglia promote tumor proliferation and
invasion, as well as support angiogenesis [39]. Microglia cell populations also
support colonization through the Wnt pathway, an effect attenuated with addition
of Wnt inhibitors [40]. Pericyte subpopulations are known to contribute to BBB
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integrity and therefore permeability. Desmin+ pericytes are found in high
concentrations in brain metastases and their presence is associated with high
permeability [41].

Taken together, the distinct physical and molecular impedance the BTB plays in
cancer treatment may seem insurmountable. In fact, the BTB, even in the
presence of heterogeneous disruption, limits drug accumulation to the degree
that there is limited apoptosis and cytotoxicity in nearly 90% of metastatic lesions
in experiments utilizing preclinical models of breast cancer brain metastasis [4247]. Inability of drugs to distribute to brain tumor tissues has led to the
progression of techniques aimed at disrupting the BBB.

2.4 BBB/BTB Disruption for Increased Therapeutic Potential.
Disruptive CNS barrier techniques have increasingly become a research focus.
Three highly investigated areas include the use of focused transcranial
ultrasound (t-FUS) coupled with intravenously delivered microbubbles,
hyperosmotic agents, and to a lesser degree radiation therapy that elicits
transient changes in BBB permeability. Each of these applied to the treatment of
metastatic brain lesions may lead to increased drug distribution and improve
efficacy of many approved therapeutics. A list of ongoing or completed clinical
trials utilizing disruption techniques can be found in Table 1.

2.4.1 Focused Transcranial Ultrasound
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Transient focused transcranial ultrasound (t-FUS) with concurrent administered
intravenous microbubbles has been investigated as it can increase barrier
permeability and improve distribution of CNS targeted therapeutics. Preliminary
studies on mechanisms of BBB disruption indicate that the minimally invasive low
intensity t-FUS coupled with the acoustic cavitation produced by the
microbubbles cause molecular changes in tight junctions through decreased
expression of claudin-5, ZO-1 and occludin, which enable the paracellular
transport of genomic and chemical therapeutics as well as initiate inflammatory
responses associated with damage-associated molecular patterns (Fig. 2.3b)
[48, 49]. Combined with the higher hydraulic conductivity of interstitial fluid to the
solid tumors, these changes have been used not only for higher tumor targeted
delivery of many small molecule therapeutics but also for genes and immune
cells [50-52].

Ultrasound influences the rate and extent of microbubble cavitation through its
physicochemical properties that may lead to the production of stable or inertial
cavitations. Under the influence of the FUS, microbubbles can undergo harmonic
or non-harmonic oscillations which are responsible for the transient tight junction
disruption; or undergo expansion and eventual collapse which can result in
supplemental leakage or permanent damage [53, 54]. The amplitude and
frequency of the ultrasound govern the mechanical index of the microbubbles
and lead to enhanced disruption by specialized mechanisms including the pushpull action mediated broadening of ECs, high shear stress through micro-stream
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production, acoustic radiation, and pressure gradient mediated microbubble
displacement [53, 55]. However, when microbubbles undergo unstable
expansions and collapse it can lead to high EC lining pressure which may cause
fragmentation of microbubbles resulting in mircro-jets and shock-waves.
Additionally, microbubbles may also undergo free radical formation depending on
microbubble lipid content and the degree of cell membrane permeabilization [56].
Altering the parameters of microbubbles enables their use as drug delivery
devices as shown by a recent study that used a novel nitrogen based folate
conjugated microbubble system encapsulated with methotrexate to increase its
site-specific delivery and thus drug efficacy using high intensity focused
ultrasound [57].

A recent study investigated the BBB/BTB penetration and cellular uptake of small
(Doxorubicin) and large (ado-trastuzumab emtansine) molecules for an
orthotopic brain metastasis of HER2 positive breast cancer model [50]. The study
demonstrated that the small hydrophobic molecule showed a much higher (7fold) concentration in the extravascular compartment along with high tumor
penetration when FUS was used as opposed to control. In contrast, despite
showing a 2-fold increase in the extravasation and slightly higher tumor
penetration, the long (4-6d) drug circulation and transient effect of ultrasound
diminished the overall effect when compared to control on day 5. Another study
investigated the antitumor efficacy of polymeric polysorbate 80 modified
paclitaxel nanoparticles and found an increase in the median survival of U87‐Luc
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glioma‐bearing mice to 37 days when to the control’s 26 days [58]. They
demonstrated that the ultrasound mediated reduction in P-gp expression and
tight junction disruption as well as apolipoprotein mediated endocytosis was
responsible for the enhanced permeation of the nanoparticles. These pre-clinical
studies in animal models have shown high efficacy leading to multiple trials to
test the use of ultrasound in drug delivery for neurological diseases including
Alzheimer’s i, Parkinson’s Disease ii with dementia and multiple gliomas iii.

Despite promising results, there are challenges such as high inertial cavitations
of the microbubbles that cause vascular and tissue damage, reliance on
expensive techniques like contrast magnetic resonance imaging to detect
disruption, and lack of normalized experimental conditions. A study to reduce the
inertial cavitation and provide an alternate treatment modality used closed loop
cavitation mechanism to accurately provide 274.3 kHz of ultrasound; increased
both survival and tumor regression by increased doxorubicin delivery in glioma
bearing rats [59]. An alternate semiautomatic approach to deliver the ultrasound
used unfocused ultrasound devices implanted in patients with glioblastoma. The
study correlated local acoustic brain pressures with signal enhancement of
greater than 10 percent observed through ultrasound which was more in gray
matter iv.

2.4.2 Radiation Therapy
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The effects of radiation therapy on the BBB have been studied since the early
1980s [60]. However, the precedent of radiation therapy with subsequently timed
chemotherapy was first suggested in 2002 by van Vulpen et. al [61]. The dose
dependent response and time course of disruption of the BBB following radiation
therapy is highly debated with the existence of contradictory reports. The
pathophysiological changes following BBB disruption induced by radiation have
been segregated into two main categories, acute and late phases [62-64]. Acute
effects are thought to occur within the first 24 hours following cranial irradiation
and, late effects are those described thereafter [65].

Mechanisms of radiation induced permeability (Fig. 2.3c) during the early stages
after therapy include EC death and an increase in neuro-inflammation.
Microvascular cell density and tight junction protein, ZO-1, expression was
shown to decrease from 1 to 180 days following a single 10Gy whole brain
radiotherapy dose [66]. A similar study reported EC density decreases at a single
10Gy dose are greatest at 10 days following radiation therapy [67]. Another study
indicating the death of ECs as an early event following cranial radiation observed
an increase in apoptotic ECs peaking at 12 hours after radiotherapy at doses
ranging from 5Gy to 100Gy [68]. From these data, it appears evident that
changes at the endothelial level occur, but the exact timing and mechanism are
not clear.
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The neuro-inflammatory response following radiation insult is characterized by
activation of astrocytes, microglia, ECs, and their inflammatory mediators.
Astrocytic and microglia activation following cranial exposure to radiation have
been indicated as early as 4 hours and as late as 6 months following radiation
treatments demonstrated by increased GFAP and CD11b staining [69, 70].
While these indicators of cellular activation are present, a number of cytokines
and adhesion molecules are also variably increased following radiotherapy. In
studies by Hong et al. and Kyrkanides et al. at four hours post radiation
treatment, increases in CNS levels of TNFα, IL-1β, and IL-6 were shown [71, 72].
In a similar study, Ruimeng et al. demonstrated the capacity for radiation therapy,
at a dose of 50Gy, to increase immune cell activation and a panel of cytokines,
including TNF-α and IL-6, at 12-weeks post treatment [73]. These research data
suggest a critical role of the neuro-inflammatory response to radiation.

Taken together, the physiological responses to radiation alter the BBB/BTB in a
manner which increases permeability. Data on the time course of increased
permeability have been reported, but are variable among studies. Wilson et al.
reported significantly altered permeability at 24 and 48 hours following cranial
irradiation with a single dose of 20Gy, which could be rescued with anti TNF-α
treatment [63]. Confirming this, a study of the rat BBB saw significant increases
in permeability peaking at 24 hours post-therapy at a single dose of 20Gy to 4.4-,
10-, 38.2-, and 70-kDa FITC-dextran molecules [74]. Interestingly in Yuan et al.’s
study, the time dependent increase in BBB permeability correlated well with an
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increase number of rolling leukocytes at the BBB, suggesting an increase in
ICAM-1, a molecule expressed on the luminal surface of the BBB to aid in
leukocyte trafficking to the brain parychema during an immune response [74].
Another study confirming early BBB disruption as soon as 24 hours following
irradiation with single doses of 20 and 40Gy [75]. Each of these studies used a
different means of irradiation, resulting in a specific dose rate for each respective
study. This may provide information regarding the effect of dose rate on
permeability related outcomes.

Another factor potentially contributing to permeability of the BBB/BTB may be
fractionation schemes. Using daily doses of 4Gy for 3 consecutive days, Crowe
et al. demonstrated enhanced permeability of irradiated tumors at 24 hours posttreatment compared to their contralateral sham treated counterparts when
analyzed using DCE MRI [76]. Fractionation may elicit potentially altered
permeability outcomes. Additionally, the particular mode of irradiation may play a
role in pathophysiologic response to irradiation as well. When comparing broad
beam radiation to micro-beam radiation therapy, Bouchet et all showed higher
permeability increases in tumors treated with microbeam radiation therapy
compared to those treated with conventional broadbeam radiotherapy at all time
points, with a maximum at 7 days following radiation treatment [77]. Of note,
there was increased permeability in lesions treated with BBRT compared to nontreated regions [77].
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These studies all provide insight as to when the permeability changes may occur
following radiation treatment. Contrary to this work another study by Murrell et al.
noted that a dose of 20Gy in 2 fractions was not able to increase tumor
permeability in a preclinical model of breast cancer brain metastasis [63]. Their
work was subjected to only two time points however, one week and 11 days post
radiation treatments. It is important to note that both authors may be suggesting
the correct response. BBB/BTB opening following radiation therapy treatment
may be transient or biphasic in nature, with points of high and low permeability in
different phases, similar to that of stroke pathology [78].

Clinically there is evidence of breakdown of the BBB and BTB after radiotherapy
as well. In a study of 30 patients receiving WBRT or SRS, with 64 analyzed
metastatic lesions, radiotherapeutic treatments improved the permeability of
initial low leaky tumors at 2 weeks and 1 month post therapy [79]. However, there
was little or decreased permeability in initially very leaky metastases [79]. Zeng
and colleagues also showed that in NSCLC patients treated with WBRT and
concurrent gefitinib therapy, increased drug penetration was observed in
accordance with escalation of radiation dose [80]. Lim et al. saw increased
gadolinium deposition in peri-tumoral areas in 44 glioblastoma patients, but no
change in untreated areas, indicating BBB/BTB disruption following radiation
therapy [81]. These date provide evidence for increased permeability following
radiation, but none give information elucidating the time course or magnitude of
increased permeability.
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2.4.3 Hyperosmotic Agents
Pre-clinical and clinical strategies have targeted the transient loosening or
disruption of the BBB to increase permeability of therapeutics by techniques such
as ultrasound, radiation or hyperosmotic agents like mannitol. One of the earliest
techniques to disrupt the BBB using hyperosmotic agents was described by
Neuwelt et al; wherein hyperosmotic mannitol administered via an intra-carotid
injection was used to reversibly disrupt the BBB in canines [82]. The work
demonstrated that when methotrexate was administered after the hyperosmotic
agent, the drug levels were significantly higher (nearly 5-9 times as compared to
control) in the ipsilateral cerebral hemisphere and contralateral hemisphere [82].
Although subsequent studies have failed to identify a singular mechanism
underlying the mannitol mediated disruption, multiple distinct phenomena have
been proposed. The most widely accepted theory of BBB opening is dehydration
of the ECs followed by vasodilation induced shrinkage or contraction of the cells
due to altered intracellular calcium levels (Fig. 2.3d) [83]. The resulting tension
along with the calcium dependent actin and cadherin interaction leads to the
widening of the tight junctions by increased bulk flow and solute diffusion. Other
factors like nitric oxide, inflammatory mediators, bradykinin and mannitol induced
tyrosine phosphorylation of Axl and beta-catenin have been implicated to
augment the BBB disruption; however the exact mechanism is still not
understood [83, 84].
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Despite facing early challenges like potential neurotoxicity, osmotic disruption
has been successfully used in pre-clinical models for improving drug therapy.
Pharmacological agents such as oligonucleotides that have poor brain delivery
have improved distribution by hyperosmotic mannitol mediated BBB disruption
[85]. The study further demonstrated a high dissemination of the oligonucleotide
in the ipsilateral brain regions including the striatum, somatosensory cortex and
thalamus upon co-administration of 25% mannitol and the oligonucleotide which
was modified with a hydrophobic moiety. In addition, the striatum, thalamus,
motor cortex, hippocampus and somatosensory cortex showed Huntington gene
mRNA silencing even a week after the initial therapy administration.

2.5 Concluding Remarks
Disruption of the BBB/BTB by ultrasound, radiation or hyperosmotic agents
appears to be a promising aid to the delivery of chemotherapy for brain
metastases. Studies using these disruptive techniques have shown to have an
auxiliary impact on the brain distribution of traditional therapy. However many
questions still remain unanswered like the length and extent of its effect,
translation to the clinic, cost to benefit and many more (see outstanding
questions). Still, these disruptive techniques in combination with chemotherapy
offer a unique system to combat the otherwise poor prognosis of brain
metastases.
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2.6 Resources
i https://clinicaltrials.gov/ct2/show/NCT03671889
ii https://ClinicalTrials.gov/show/NCT03616860
iii https://ClinicalTrials.gov/show/NCT03608553
iv https://ClinicalTrials.gov/show/NCT02253212
v https://ClinicalTrials.gov/show/NCT02861898
vi https://ClinicalTrials.gov/show/NCT03714243
vii https://ClinicalTrials.gov/show/NCT03322813
viii https://ClinicalTrials.gov/show/NCT02343991
ix https://ClinicalTrials.gov/show/NCT03712293
x https://ClinicalTrials.gov/show/NCT03626896
xi https://ClinicalTrials.gov/show/NCT02031237
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Glossary

Active Transport: The movement of molecules into the cell across the cellular
membrane assisted by enzymes.

Blood-Brain Barrier: The physicochemical barrier existing at the interface
between the systemic circulation (blood) and brain limiting the passive and active
transport of small molecules, proteins, toxins, and other potentially pathogenic
entities into the brain.

Blood-Brain Barrier Disruption: A physical opening, transient or persistent, of the
BBB or BTB through a variety of mechanisms with the intent of increasing
distribution of therapeutics into brain tissues.

Blood-Tumor Barrier: Similar to the BBB in healthy individuals, the BTB is the
interface between the blood and metastatic or primary tumor cells. This barrier is
inherently “leaky” due to lack of tight junctions and neo-angiogenesis induced by
the tumor.

Brain Metastases: Tumors formed in the brain by cancer cells that have detached
and migrated from a primary tumor site.
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Central Nervous System: Comprised of the brain and spinal cord, this complex of
nerves controls the activities of the body.

Endothelial Cells: Cells that line the interior (luminal) surfaces of blood and
lymphatic vessels.

Focused Transcranial Ultrasound: The use of low frequency ultrasonic waves,
penetrating through the cranium to target particular sites within the brain.

Glioblastoma: Also known as glioblastoma multiforme. A form of primary CNS
tumor arising from one of the glial cell types.

Neo-angiogenesis: The growth of new blood vessels.

Passive Diffusion: The movement of molecules across a membrane or between
cells without the need for energy. Molecules down a concentration gradient, from
a high concentration to a lower concentration.

Radiation Therapy: The use of X-rays, or similar forms of radiation, in the
treatment of cancer.
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Title
Super-selective

Trial number

Mode of disruption

NCT02861898

Intra-arterial Mannitol

Type of disease
Glioblastoma

Intra-arterial

Brain Neoplasm,

Repeated Infusion

Malignant EGFR

of Cetuximab for

Gene

the Treatment of

Overexpression

Newly Diagnosed

GBM

Glioblastoma
Blood Brain Barrier
Disruption (BBBD)

NCT03714243 ExAblate Model 4000
Type-2

Her-2 positive
Breast Cancer,

Using MRgFUS in

Brain

the Treatment of

Metastases

Her2-positive
Breast Cancer
Brain Metastases
(BBBD)
ExAblate Blood
Brain Barrier

NCT03322813 ExAblate 4000 - Type
2

Disruption (BBBD)
for Planned
Surgery in
Glioblastoma
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GBM

Assessment of
Safety and

NCT03616860

ExAblate Neuro Model Glioblastoma
4000 Type 2.0

Feasibility of
ExAblate BloodBrain Barrier (BBB)
Disruption for
Treatment of
Glioma
Blood-Brain Barrier

NCT02343991 Transcranial ExABlate

Brain Tumor

Disruption Using
Transcranial MRIGuided Focused
Ultrasound
ExAblate Blood-

NCT03712293 ExAblate 4000 type 2.0 Glioblastoma

Brain Barrier

Multiforme

Disruption for
Glioblastoma in
Patients
Undergoing
Standard
Chemotherapy
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Safety of BBB

NCT03626896 Neuronavigation-

GBM,

Disruption Using

guided focus

Neoplasm,

NaviFUS System in

ultrasound system

glioma

Recurrent

(NaviFUS)

Glioblastoma
Multiforme (GBM)
Patients
Safety of BBB

NCT02253212 SonoCloud

Glioblastoma,

Opening With the

Glioma, Brain

SonoCloud

Tumor

(SONOCLOUD)
MRI Study of

NCT02031237

SRS, Fractinated

Brain

Changes in Blood-

WBRT, Fractionated

Metastases

Brain/Tumor-

SRS

(Breast, Lung,

Barrier Permeability

Melanoma, etc.)

in Patients With
Brain Metastases
During and After
Radiotherapy

Table 2.1. BBB/BTB disruption techniques in ongoing or completed clinical
trials.
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Figure 2.1. Normal blood-brain barrier anatomy and physiology. Brain
capillary endothelial cells are tightly held to one another through continuous tight
junction proteins and express P-glycoprotein (P-gp) and Breast cancer resistant
protein (BCRP) efflux transporters. Astrocytic end-feet processes further seal and
support BBB integrity. Pericytes further regulate cerebral blood flow and BBB
permeability. Microglia, the brain’s resident immune cells, can influence BBB
permeability through inflammatory cascades and serve as the innate response to
pathogens within the brain.
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Figure 2.2. The blood-tumor barrier has altered anatomy and physiology.
Cancer cells coopt the cerebral vasculature and induce neo-angiogenesis
resulting in fenestrated endothelia lacking tight junctional expression.
Fenestrated, mal-formed vasculature allows for heterogeneous uptake of drug
solutes. Cancer cells have increased expression of the P-gp and BCRP efflux
transporters. At the BTB, less astrocytic end-foot processes and pericytes exist
contributing to altered BTB integrity.
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Figure 2.3. Blood-brain barrier disruption techniques. Normal, undisrupted
BBB with non-fenestrated endothelial cells sealed by tight junction proteins,
further supported by astrocytic end-feet, pericytes, and microglia (a). Focused
ultrasound (yellow curves) in combination with intravenously injected disrupts the
BBB through cavitation and acoustic forces, ultimately leading to decreased
molecular expression of tight junction proteins and an inflammatory response (b).
Radiation therapy (yellow lines) disrupts the BBB through mechanisms of
endothelial cell death and a neuro-inflammatory response from astrocytes and

39

microglial cells (c). Hyperosmotic solutions are able to induce contraction and
shrinkage of endothelial cells through a calcium dependent mechanism
prompting widening of tight junctions (d).
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Chapter 3
The hypomethylating agent azacitidine is effective in treating
brain metastasis of triple negative breast cancer through
regulation of DNA methylation of keratin 18 gene.

3.1 Introduction
Breast cancer is the second leading cause of cancer with the highest mortality
rate in females in the United States (1). Based on genetic profiling, breast cancer
is classified into four subtypes: luminal A (ER+ and/or PR+, HER2-, low Ki67
index), luminal B (ER+ and/or PR+, HER2+ or -, high Ki67 index), HER2 positive
(HER2+, ER-, PR-), and triple negative (ER-, PR- and HER2-) (2). For drug
treatment of receptor positive breast cancers, therapeutics that specifically target
the hormone receptors and HER2 are available (3). However, for triple negative
breast cancer, which is associated with an unfavorable prognosis, there are no
targeted therapies, leaving patients with traditional chemotherapeutic agents that
have significant adverse effects (4). In some patients, tumors metastasize to
different locations within the body including lungs, liver, bones or brain. Once the
lesion disseminates to brain, average patient survival time is less than one year,
and treatments including chemotherapy, radiation and surgery are the primarily
palliative options (5).
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DNA methylation is an epigenetic mechanism used by cells to control gene
expression (6). In normal cells, DNA methylation ensures proper regulation of
gene expression and silencing. Abnormal DNA hypermethylation, may result in
dysregulation of these mechanisms resulting in altered gene function (7). Cancer
is associated with altered DNA methylation leading to inhibition of tumor
suppressor genes and compaction of chromatin (8, 9). Hypermethylation of
numerous tumor suppressor genes is recognized in multiple cancer types and
this phenomenon may contribute to the initiation and/or progression of the
disease (10, 11). Of relevance to this study, multiple genes that are critical in
breast carcinogenesis are hypermethylated including; the tumor suppressors
p16, p53 and BRCA1, cell cycle regulator CCND2, and cell growth regulators ER
and PR, as well as others (12-14).

Hypomethylating agents such as azacitidine (or azacytidine, AZA) and its deoxylderivative decitabine have been approved by the U.S. FDA to treat patients with
hematological malignancies such myelodysplastic syndromes (MDS) (15).
Although their use in breast cancer treatment are not approved for clinical use,
DNA hypomethylating agents have been shown to activate tumor suppressor
genes. It should be noted that when given intravenously, AZA crosses the bloodbrain barrier (BBB) and reaches cytotoxic levels in cerebrospinal fluid (16, 17). In
this study, we evaluated the anti-tumor effects of the hypomethlyating agent AZA
in a preclinical model of triple negative breast cancer brain metastasis and
observed AZA has efficacy as a novel chemotherapeutic agent.
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3.2 Materials and Methods
Cell lines and chemicals
The parental regular triple negative breast cancer MDA-MB-231 (abbreviated as
“231”) cell line was purchased from ATCC (Manassas, VA). The brain colonizing
counterpart of 231 cells (“231Br” cells), also known as tropic or brain seeking 231
Br cells, were isolated from brain lesions in the brain metastasis of breast cancer
mouse model we previously generated. These cells were kindly provided by Dr.
Patricia Steeg from the National Institute of Health Center for Cancer Research.
Both cell lines were cultured at 37 oC, 5% CO2, in Dulbecco's modification of
eagle's medium (DMEM) (Corning, Inc., Corning, NY) containing 10% fetal
bovine serum (VitaScientific, Inc., College Park, MD), 10 mM L-glutamine
(Thermo Fisher Scientific, Waltham, MA), and 1X penicillin/streptomycin (Thermo
Fisher Scientific, Waltham, MA). AZA was purchased from Sigma-Aldrich Inc. (St.
Louis, MO).

Western blotting
The Western blotting assay was described previously (18). Briefly, cell lysates
were prepared in RIPA buffer and protein samples were loaded on a SDSpolyacrylamide gel, separated by electrophoresis and subsequently transferred
to a PVDF membrane. Membranes were blocked with 5% milk in 1X TBS
containing 0.05% (v/v) Tween-20 for 4 hours at room temperature and washed
seven times with 1X TBS and 1X TBST alternatively. Membranes were then
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incubated with primary antibody overnight at 4 °C, followed by incubation with
secondary antibody at room temperature for 1 hour. Pierce supersignal
chemiluminescent substrates were used and images were captured by using the
G:BOX Chemi XX9 gel doc system (Syngene Inc., Frederick, MD). Detailed
information of the antibodies is listed in Supp. Table 1.

MTT assay
The cell viability was measured using the MTT assay kit (ATCC, Inc., Manassas,
VA) and the manufactory’s protocol was followed. Briefly, 1,000 cells in 100 l
were plated in each well in a 96-well plate and incubated overnight. On the next
day, the cell medium was replenished and various concentrations of AZA were
added to each well (triplicate) accordingly and incubated at 37°C for 72 hours.
After incubation, 10 l of MTT reagent was added to each well and the plate was
incubate at 37°C for 4 hours. 1000 l of detergent reagent was then added to
each well and the plate was left at room temperature in the dark for 4 hours. The
optical density of absorbance at 570 nm was recorded using a Synergy2 multimode microplate reader (Biotek, Inc., Winooski, VT). The cell viability was
calculated based on the optical density value normalized to blank control. The
IC50 of AZA in 231 and 231 Br cells were calculated based on the cell viability
measured by three independent MTT assays.

Apoptosis assay
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Cell apoptosis was measured using the PE Annexin V apoptosis detection kit
(BD Biosciences, Inc., San Jose, CA). The manufacturer’s protocol was followed
and the percentage of apoptotic cells was detected and analyzed using the BD
Accuri C6 flow cytometry (BD Biosciences, Inc., San Jose, CA).

ELISA assay
After cells were treated with various concentrations of AZA for 72 hours, the
secreted VEGF in the medium was measured by using the human VEGF ELISA
kit (Sigma-Aldrich, Inc., Saint Louis, MO). The ELISA assay was described
previously, and the manufacture’s protocol was followed (19). Briefly, 100 l of
each standard and medium sample was mixed and added into 96-well plates and
incubated for 2.5 hours at room temperature with gentle shaking. The
supernatant was then discarded and washed 4 times with 1X washing solution.
100 l of 1X prepared biotinylated detection antibody was added for 1 hour at
room temperature with gentle shaking. The solution was discarded and washed,
and 100 l of prepared HRP-conjugated streptavidin solution was added and
incubated for 45 minutes at room temperature with gentle shaking. The solution
was discarded and 100 l of ELISA colorimetric TMB reagent was added and
incubated for 10 minutes at room temperature in the dark with gentle shaking.
Finally, 50 l of stop solution was added and the plate was read at 450 nm using
a Synergy2 multi-mode microplate reader (Biotek, Inc., Winooski, VT). The
amount of VEGF present in the cell culture medium was normalized to the
number of cells present at the time of collection.
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In vitro cell migration assay
The transwell migration assay was described previously (20, 21). After cells
were treated with various concentration of AZA for 72 hours, they were washed
with PBS and resuspended in serum-free medium. 600 l of regular medium
containing 10% serum was added to one well of a 24-well plate, then the
migration chamber (Millipore Inc, PI8P01250) was replaced in the well. 100 l of
serum-free medium was first added in each chamber, then a total of 105 cells in
200 L serum-free medium was added to the chamber. The plates were
incubated at 37°C for various times (3, 16, and 72 hours). At the end of the
designated time point, medium in the chamber was removed and the chambers
were gently washed twice with PBS. Cells were fixed with formaldehyde (3.7% in
PBS) at room temperature for 20 minutes, followed by PBS wash and
permeabilization by 100% methanol at room temperature for 20 minutes. After
removal of methanol and washing with PBS, cells were stained with 1% crystal
violet at room temperature for 20 minutes. Excess crystal violet was removed
and cells were washed with PBS. Finally, cells on the chamber were counted
under the light microscope (average number of five microscope fields).

In vitro cell invasion assay
The cell invasion assay was described previously (20, 21). 24-well plates
containing matrigel invasion chambers (Corning Inc., Corning, NY) were preincubated at 37°C overnight. Similar to the procedure used in the cell migration
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assay, the same number of cells (105 cells in 200 l serum-free medium) were
plated in each well, and the plates were incubated at 37°C for pre-designated
periods (16, 72, and 96 hours). After reaching the time point, cells were fixed,
permeabilized , stained, and counted under the light microscope using the same
techniques as the cell migration assay.

Wound-healing assay
The wound-healing assay (also known as in vitro scratch assay) has been
described previously (20, 21). 106 of the 231 and 231Br cells were plated in sixwell plates and incubated at 37°C overnight. On the next day, after confirming
that the cells were attached to the well and cell confluence reached ~70%, a
scratch was made in each well using a 1 mL pipette tip, and medium containing
increasing concentrations of AZA was added to each replicate. The number of
cells present in the scratch made on day 0 was counted for each pre-designated
time (24, 48, 72, and 96 hours) and pictures of the denuded area were taken
using an Olympus IX50 inverted system microscope (Olympus, Inc., Center
Valley, PA) every day for 5 days.

Detection of the keratin 18 gene by PCR
DNA from both cell lines was extracted and purified using the GeneJet genomic
DNA purification kit (Thermo Fisher Scientific, Waltham, MA) based on the
manufacturer’s protocol. The pair of primers designed to measure the keratin 18
gene by PCR is forward 5’-CTGGCCTCTTACCTGGACAGAGTGAG-3’and
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reverse 5’-TGT GGCTAGGTGCGCGGATGGAAATCC-3’, which yields a 300bp
PCR product. The PCR reaction was set up by using the iProof high-fidelity PCR
kit (Bio-Rad Laboratories, Inc., Hercules, CA) and was performed with an
Eppendorf Mastercycler thermocycler (Hamburg, Germany). The PCR thermal
cycling protocol was as follow: initial denaturation at 98 °C for 30 seconds,
denaturation at 98 °C for 10 seconds, annealing at 65 °C for 30 seconds, and
extension at 72 °C for 30 seconds, a total of 30 cycles, and final extension at 72
°C for 10 minutes.

Real-time PCR
The real-time PCR procedure was described previously (18). Briefly, cells were
harvested by centrifugation at 1500 g for 5 minutes at 4°C, resuspended in 250 μl
1X PBS, then lysed by adding 750 μl Trizol LS reagent (Invitrogen, Inc.,
Carlsbad, CA). RNA was then isolated following the manufacturer’s protocol and
was subsequently resuspended in 30 μL of RNase-free water. The RNA
concentration was measured using a Synergy2 multi-mode microplate reader
(BioTek Inc., Winooski, VT). The TURBO DNA-free kit (Thermo Fisher Scientific
Inc., Waltham, MA) was used to remove DNA contamination within each sample.
The first-strand cDNA was synthesized using the SuperScript III first-strand
synthesis system (Thermo Fisher Scientific Inc., Waltham, MA) following the
manufacturer’s protocol. FAM-MGB primer/probe mixes for keratin 18
(Hs02827483_g1), VEGFA (Hs00900055_m1), and GAPDH (Hs02786624_g1)
were used for real-time PCR TaqMan gene expression assays (Applied
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Biosystems Inc., Foster City, CA). All real-time PCR reactions were performed in
duplicate with no-RT control and water control on the StepOnePlus real time
PCR system (Applied Biosystems Inc., Foster City, CA). Individual cDNA
samples were normalized according to their levels of GAPDH and the relative
standard curve method was used for analysis.

Sequencing of the intron 1 region of the keratin 18 gene in both cell lines
In order to compare the DNA sequence of intron 1 region (737bp) of the keratin
18 gene between 231 and 231 Br cells, we designed a pair of primers and used
PCR to amplify the desired region. The forward sequence was 5’GATCATCGAGGACCTGAGGG-3’, the reverse sequence was 5’-GGGGAGC
AGATCCTTCTTAGC-3’. The PCR reaction was set up using the DreamTaq hot
start green DNA polymerase kit (ThermoFisher Scientific, Inc., Waltham, MA)
and PCR was performed with the Bio-Rad MJ mini personal thermal cycler #
PTC114 (Bio-Rad Laboratories, Inc., Hercules, CA). The PCR thermal cycling
protocol was as follow: initial denaturation at 95 °C for 2 minutes, denaturation at
95 °C for 30 seconds, annealing at 60 °C for 30 seconds, and extension at 72 °C
for 45 seconds, a total of 19 cycles, then followed by dropping 0.5 °C each time
to 50 °C, 95°C for 30 seconds, 50 °C for 30 seconds, 72 °C for 30 seconds, a
total of 19 times. The final extension was at 72 °C for 10 minutes. This yielded a
single and clear 906bp PCR product. The PCR product was cloned into the
pCR2.1-TOPO vector using the TOPO TA cloning kit (Invitrogen, Inc., Carlsbad,
CA) following the manufacturer’s protocol. The cloning product was then
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transformed into DH5-alpha E.coli competent cells (Invitrogen, Inc., Carlsbad,
CA). The transformations were spread on ampicillin-selective plates and
incubated overnight at 37°C. Colonies were picked and cultured in LB medium
containing 100 g/ml ampicillin with shaking at 250RPM overnight at 37°C. On
the next day, plasmid DNA was isolated by using the Invitrogen PureLink quick
plasmid miniprep kit (Invitrogen, Inc., Carlsbad, CA). Plasmid DNA samples from
five positive colonies were send to the West Virginia University Genomics Core
Facility for sequencing.

Keratin 18 gene DNA methylation determination by bisulfite chemical
modification
The genomic DNA from 231 and 231Br cells was isolated using the GeneJET
genomic DNA purification kit (ThermoFisher Scientific, Inc., Waltham, MA)
following the manufacturer’s protocol. The genomic DNA was then treated with
bisulfite to chemically modify non-methylated cytosines into uracil using the EZ
DNA methylation-lightning kit (Zymo Research, Inc., Irvine, CA) following the
manufacurer’s protocol. In this treatment, unmethylated cytosine residues were
converted to uracil, while methylated cytosine residues were resistant to bisulfite
modification and remained as a cytosine residue. In order to measure and
compare the DNA methylation of the keratin 18 gene in both cell lines, five pairs
of primers were designed and used to fully cover and amplify the bisulfite
modified intron 1 region of keratin 18 gene by PCR. The sequences of the five
pairs of primers were: Pair 1 forward: 5’- TTAATTATYGGTTTTTG
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GGTTTTGTTTAGG-3’, reverse: 5’-RATCTCCAAACTCCTCA CTCTAT-3’; Pair 2
forward: 5’-TTGGATAGAGTGAGGAGTTTGGAGA-3’, reverse: 5’AAAAATCCAAATATACCC AACCCCCT-3’; Pair 3 forward: 5’GGAGGGGGTTGGGTATATTT-3’, reverse: 5’-CACCC
TAAATTAACTCCTCCCAAAA-3’; Pair 4 forward: 5’TTGAGTTATTTAGGAGTAAAT AAGAGGTTTTTTTTTG-3’, reverse: 5’CCAAAAATAACCAAAAACTCTCCCTAAA-3’; Pair 5 forward: 5’TGGTTATTTTTGGGATTAGGAAGTTTTTATTAG-3’, reverse: 5’-CAAA
ATCCCACTATAAACCCCTAACT-3’. The methods used in the PCR reaction set
up and performance, TOPO TA cloning, and plasmid DNA isolation were the
same as described above. Each of the five pairs of primers yielded a single and
clear PCR band using bisulfite converted genomic DNA as the template from
both cell lines (Supp. Fig. 4). Finally, plasmid DNA samples from five positive
colonies generated from each pair of primers were sent to West Virginia
University Genomics Core Facility for sequencing.

HhaI restriction digestion
The HhaI restriction enzyme was purchased from New England BioLabs, Inc.
(Ipswich, MA). 20 l restriction digestion reaction containing 500 ng genomic
DNA isolated from 231 or 231Br cells and 1 l HhaI was set up following the
manufacturer’s protocol. The reaction was incubated in a 37°C water bath
overnight allowing the full digestion of DNA by HhaI. The pair of primers
designed used to detect the HhaI digestion site is forward: 5’-
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GGAGGGGGTTGGG CATACT-3’, reverse: 5’CACCCTGGATTGGCTCCTCCCAAAG-3’. If DNA methylation prevented
digestion of the keratin 18 gene, the DNA would not be digested by HhaI and this
primer would yield a ~300bp PCR product. On the contrary, if the DNA was
digested by HhaI, no such a ~300bp PCR product would be formed. A pair of
primers designed and used as positive control to detect the keratin 18 gene was
forward: 5’-AGCTAGAC AAGTACTGGTCTCAGCAG-3’, reverse 5’CAGCTCTGACTCAAGGTGCAGCAGGAT-3’. Regardless of digestion status of
the keratin 18 gene digested by HhaI, this primer could detect the presence of
the keratin 18 yielding a ~300bp PCR product in both cell lines. Methods used in
PCR reaction set up and performance were the same as described above.

Survival of animals with preclinical brain metastases of breast cancer treated with
AZA
Animal experiments were approved by the Institutional Animal Care and Use
Committee at the West Virginia University. Use of the brain metastasis breast
cancer in vivo mouse model has been described previously (22, 23). Briefly, the
brain tropic breast cancer 231Br cells were isolated by repeated cycles of
intracardiac injection of the parental 231 cells, harvesting of brain metastases,
and ex vivo culture of isolated cells. These brain metastatic cells were injected
into the left cardiac ventricle, circulated in the peripheral vasculature, arrested in
brain capillaries, with subsequent extravasation across the in vivo BBB, and
developed metastatic lesions in mice. The presence of metastatic tumors was
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confirmed on day 21 after intracardiac injection with bioluminescent imaging (BLI)
using the IVIS Spectrum CT imaging system (PerkinElmer, Waltham, MA). After
tumor burden confirmation on day 21, mice were intraperitoneally administered
with AZA (2.5mg/kg) or vehicle control (PBS) in a total of four cycles. In each
cycle, AZA or PBS was injected for five continuous days, stopped for two days,
and then again followed by another five continuous days. Between each cycle,
there was a two-week off interval. Tumor burden was monitored twice weekly
and quantified using BLI assay, similar to our previous work (22, 23). Mice were
introperitoneally injected with D-luciferin potassium salt (150mg/kg body weight,
PerkinElmer Inc., Waltham, MA) and then the brain bioluminescent signal was
captured 15 minutes after injection of luciferin. Animals were euthanized under
anesthesia at the presentation of neurological symptoms or when moribund.
Statistics. Statistical significance of the data between two groups was analyzed
by the Student t-test (Prism 8). Statistical significance of the data with more than
two groups was analyzed by one-way ANOVA with a Tukey post-test (Prism 8).
Significance levels were set at p<0.05 (*), p<0.01 (**), and p<0.001 (***).

3.3 Results
Brain colonizing breast cancer cells display a different growth pattern compared
to parental breast cancer cells.
After intracardiac injection, the parental triple negative breast cancer cells (231)
are disseminated throughout the body (Fig. 3.1a), while the brain colonizing cells
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(231Br) are primarily distributed to the brain (Fig. 3.1b).. The fold change of cell
growth suggest the 231Br cells replicate faster than the 231 cells (Fig. 3.1c).

Brain colonizing breast cancer cells are more sensitive to AZA treatment
compared to regular cancer cells.
The IC50 value of AZA in 231Br and 231 cells was determined using an MTT
assay. We observed IC50 values for AZA was 83.3 ± 8.8 M in 231Br cells and
48 ± 4.9 M in 231 cells (p<0.01, Fig. 3.2a and Supp. Fig. 3.1a), suggesting
differential sensitivity to AZA. In subsequent experiments both lines were treated
with a range of AZA concentrations (0 – 500 M) for 72 hours, and apoptosis
was calculated by a percentage of Annexin-V positive cells using flow cytometry.
At concentrations of 20 M and 100 M of AZA, a greater degree of apoptosis
was induced in 231Br cells compared to 231 cells (p<0.001). However, 500 uM of
AZA caused apoptosis at similar level in both cell types (Fig. 3.2b and Supp. Fig.
3.1b). The expression of the anti-apoptotic protein BCL-2 decreased in 231Br
cells upon AZA treatment, with little effect in the 231 cells. However, expression
BCL-xL was not detected in either cell lines (Fig. 3.2c and Supp. Table 3.2).
Further, there was an increased expression of the pro-apoptotic proteins
caspase-3 and caspase-9, when AZA was exposed to the 231Br cells in a dosedependent manner (Fig. 3.2d and Supp. Table 3.2). However, expression of two
other two pro-apoptotic proteins BAD and BAX proteins remained unchanged
after AZA treatment in (Supp. Fig. 3.1c).
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AZA inhibited the Wnt signaling transduction pathway in brain colonizing breast
cancer cells.
Treatment with AZA in 231Br cells for 72 hours inhibited expression of Wnt-3,
Wnt-4, glycogen synthase kinase-3 (GSK-3), and beta-catenin in a dose
dependent manner as determined by a western blot (Fig. 3.3a). In contrast,
treatment with AZA in 231 cells did not change Wnt-3 expression significantly,
but at a higher concentration (100 M), AZA inhibited expression of Wnt-4, GSK3 and beta-catenin in these cells (Fig. 3.3a). AZA treatment had no effect on
Wnt-1 expression in either cell types and the expression of Wnt-5, Wnt-11, and
adenomatous polyposis coli (APC) was undetectable in both lines (Supp. Fig.
3.2a). While there were changes in the Wnt signaling transduction pathway there
was no significant impact on either the Ras/Raf/MEK/MAPK or the
PI3K/Akt/mTOR pathways in either cell line (Supp. Fig. 3.2b and 3.2c).

Angiogenesis related markers were decreased by with AZA treatment in both cell
lines.
Angiogenesis-related markers were measured in both cell lines treated by
different concentrations of AZA. At higher concentrations (100 M), AZA
treatment for 72 hours decreased expression of vascular endothelial growth
factor (VEGF) receptor 2 only in the 231Br cells. Treatment with AZA had no
significant impact on hypoxia-inducible factor (HIF)-1 alpha expression in either
cell lines (Fig. 3.3b). However, expression of VEGF, VEGF-receptor 1, and
transforming growth factor (TGF) beta was undetectable in either types of cells
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(Data not shown). The mRNA was measured by real-time PCR (Fig. 3.3c) and
the secreted VEGF into the cell culture medium was measured by ELISA assay
(Fig.3d) in both lines treated with AZA. Cellular VEGF mRNA level in 231 cells
was significantly higher in 231 cells compared to 231Br cells (p<0.001) and AZA
treatment did not have significant impact on VEGF mRNA levels in both cell lines
(Fig. 3.3c). However, AZA reduced the amount of VEGF secreted into the
medium in a dose-dependent manner in both cell lines (Fig. 3.3d).

Brain colonizing cells have higher migration and invasion potential.
After incubation, we did not observe significant changes in cell number with AZA
at early time points, but after 72 hours of incubation, 231Br cells had higher
migration potential (p<0.001, Fig. 4a and Supp. Fig. 3.3a). Similarly, in the cell
invasion assay, at early time points (16 and 72 hours) there were no significant
differences between the cell lines, (Supp. Fig. 3.3b) but at 96 hours 231Br cells
(without AZA) had increased migration (p<0.05, Fig. 3.4b). Of interest, AZA
treatment did not significantly impact cell invasion in either lines (Fig. 3.4b and
Supp. Fig. 3.3b). Consistent with cell migration and invasion assays, the wound
healing assay showed that the 231Br cells migrated faster than 231 cells. After
72 hours of AZA treatment, the width of wound was still present in 231 cells, but
not in 231Br cells (Supp. Fig. 3.3d-3.3e). In addition, AZA treatment significantly
inhibited wound healing in both lines after 48 hours (Fig. 3.4c and Supp. Fig.
3.3c-3.3e).
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Hallmark metastasis markers are higher in the brain colonizing cell line.
Matrix metalloproteinases (MMPs) such as MMP2, MMP7 and MMP9 are
metastasis markers in breast cancer (24, 25). MMP2 was expressed in both cell
lines but greater in 231Br cells, and MMP9 expression was not seen in 231 cells
but detected in 231Br cells. Interestingly, AZA treatment for 72 hours had no
significant impact on expression of MMP2 and MMP9 in either cell line (Fig.
3.4d). Epithelial markers including E-cadherin and cytokeratins, and
mesenchymal markers N-cadherin were measured with and without AZA
treatment in both cell lines (26). Expression of E-cadherin was not detected in
either cell line (Data not shown), while vimentin was present at similar levels in
both cell types. N-cadherin expression was only detected in 231Br cells.
Treatment with AZA decreased expression of N-cadherin in 231 cells (Fig. 3.4d).
Since cytokeratin expression is decreased during the EMT process (27), we
measured their expression profile using a pan-cytokeratin antibody mixture of
AE1 and AE3. This was done to detect multiple members of the cytokeratin
family of proteins (1-6, 7-10, 14-16, and 19). We observed expression of
cytokeratins measured by the pan-cytokeratin antibody was lower in 231Br cells
compared to 231 cells. In addition, higher concentrations of AZA (50 M and 100
M) treatment further decreased expression in the 231Br line (Fig. 3.4d).

DNA methylation is altered in brain colonizing cells compared to parental cancer
cells.
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Cytokeratin 18 is an epithelial cytokeratin coded by the keratin 18 (or KRT18)
gene (28). We detected expression of keratin 18 protein in 231 cells but not in
231Br cells, despite the presence of the keratin-18 gene being present as
detected by real-time PCR (Fig. 3.5a and 3.5b). Also, it should be noted that the
mRNA levels of the keratin gene 18 were significantly lower in the 231Br cells
(p<0.001, Fig. 3.5c). We noted that AZA treatment increased keratin 18KRT18
mRNA significantly in a dose dependent manner in 231Br cells (every dose
increased with significance at p<0.05 or lower, Fig. 3.5c). Based on this data, we
hypothesized that decreased gene expression may be due to DNA
hypermethylation. It has been shown DNA methylation of intron 1 in the keratin
18 gene is important in regulating expression (29). We did not detect DNA
mutation or deletion of this region (737 bp) of the keratin 18 gene in ether cell
line, and the DNA sequence is identical (Data not shown). We sequenced and
compared DNA methylation of the intron 1 region in the two cell lines by using
the bisulfite conversion method. We observed three cytosine residues were
converted into uracil in 231 cells while they remained unchanged in 231Br cells
(Fig. 3.5d). Among the three identified different cytosine sites, one is the target of
the HhaI restriction enzyme (Fig. 3.5d). To further confirm the difference in
particular cytosine methylation, the genomic DNA from both cell lines was
digested with HhaI following PCR using designed primers. A ~300bp band was
detected in 231Br cells, but not in 231 cells, confirming cytosine methylation of
keratin gene (Fig. 3.5e). DNA methylation is catalyzed by DNA
methyltransferases (DNMTs) which include two major types DNMT3a and
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DNMT3b and accordingly we measured the expression of the enzymes with AZA
treatment (6). The expression of DNMT3a was only detected in 231Br cells and
the expression of DNMT3b was undetectable in either cell types (Fig. 3.5f). AZA
treatment decreases the DNMT3a expression in 231Br cells indicating AZA can
potentially inhibit the process of DNA methylation in brain colonizing cells (Fig.
3.5f).

AZA decreased tumor burden and prolonged survival in mice with brain
metastases of breast cancer.
To determine if AZA treatment improved survival and control of tumor burden in
vivo, we injected mice intracardially with the 231Br cells and allowed for
development of metastatic brain lesions (22, 23). After 21 days, tumor bearing
mice were randomized into vehicle (PBS) and drug treatment (AZA, 2.5mg/kg
body weight) groups. We observed that in 2.5mg/kg AZA treated mice, tumor
burden was significantly lower compared to vehicle treated mice (p=0.0112, Fig.
3.6a). We also noted that AZA treatment significantly increased survival when
compared to vehicle treated mice, with the median survival of 50 and 42 days
respectively (p=0.0026, Fig. 3.6b).

3.4 Discussion
DNA methylation is an epigenetic mechanism used by cells to control gene
expression (6). DNA hypermethylation may cause improper gene silencing,
leading to the downregulation of gene expression and alleviation of gene
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function. Hypermethylation of numerous tumor suppressor genes has been
identified in multiple cancer types suggesting that DNA hypermethylation may
contribute to the initiation, development, and increased metastatic capacity of
cancer (7, 10).

The hypomethylating agent AZA and its deoxyl derivative 2'-deoxy-5'-azacytidine
(decitabine) were developed as pyrimidine nucleoside analogs in 1960s. Later, it
was observed that the compounds inhibit DNA methylation in human cell lines
(30). Studies of AZA also showed antitumor activity in hematological
malignancies including MDS, acute myeloid, chronic myeloid, and acute
lymphocytic leukemia (31). Concurrent epigenetic work showed that multiple
important genes are hypermethylated in MDS patients. One of the genes is tumor
suppressor gene CDKN2B which encodes the cyclin dependent kinase inhibitor
p15INK4b. Other hypermethlated genes in MDS patients include the calcitonin
gene, HIC, E-cadherin and estrogen receptor (32). The led to the FDA approval
of AZA as the first therapy for all subtypes of MDS in 2004 (33). With relevance
to this work, in breast cancer multiple genes (e.g., p16, p53, and BRAC1) are
also hypermethylated (12-14). Breast cancer brain metastasis poses a lifethreatening problem for women with advanced metastatic breast cancer and
current chemotherapeutic agents are largely ineffective against brain metastases
(34-38). In this study, we tested the effectiveness of the hypomethylating agent
AZA in treating brain metastasis of breast cancer using a combined in vitro cell
and in vivo approach (22, 23).
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We observed that the IC50 value of AZA in 231Br cells was significantly lower
than in 231Br cells (Fig. 3.2a) and AZA treatment triggered a higher percentage
of apoptosis in 231Br cells compared to 231 cells (Figs. 3.2b-3.2d). Further, AZA
inhibited BCL-2 expression in 231Br cells in a dose-dependent manner
suggesting inhibition of anti-apoptotic BCL-2 may be a mechanism of anti-tumor
therapeutic response induced by AZA in these cells. Overall, these results
suggest 231Br cells are more sensitive to AZA treatment. In triple negative breast
cancer, Wnt signaling regulates cell differentiation, proliferation and stem cell
pluripotency (39, 40). Accordingly, we examined AZA effects in Wnt signaling,
and observed expression of Wnt-3, Wnt-4, GSK-3, and beta-catenin were
inhibited by AZA in a dose dependent manner in 231Br cells (Fig. 3.3a). As betacatenin is required for the tumorigenic behavior of triple-negative cancer cells,
our results suggest AZA inhibits Wnt signaling as well as tumorigenesis in brain
colonizing cells more (41). Consistent with previous literature, we did not
observe differences in the Ras/Raf/MEK/MAPK and PI3K/Akt/mTOR pathways
as they have greater influence in HER2+ cancer (Supp. Fig. 3.2b and 3.2c) (42).
We also observed that AZA treatment inhibits of angiogenesis related markers
(Fig. 3.3) and cell migration and invasion (Fig. 3.3a). Collectively, in vitro results
support the hypothesis that AZA is effective in treating brain metastasis of breast
cancer in vivo.
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The BBB acts as a physiological and biochemical barrier that restricts the
passage of many hydrophilic and large molecular weight compounds. AZA is a
nucleic acid synthesis inhibitor with a molecular weight of 244.2g/mole and a
XLogP3 of -1.9. Strictly based on its physicochemical properties, AZA serves as
a model compound to cross biological membranes like the BBB with an ideal
range of molecular weight, lipophilicity, and hydrogen bond donors and
acceptors. Additionally, its relatively high aqueous solubility and stability renders
it as a potentially advantageous investigative chemotherapeutic for brain delivery
(43-46). Since AZA is able to cross the BBB (16, 17), we next used an in vivo
mouse model of brain metastasis of breast cancer and treated animals with AZA
(2.5mg/kg body weight) or vehicle control (PBS). Our in vivo studies showed that
the overall survival of AZA treated mice was significantly increased compared to
mice treated with PBS (Fig. 3.6a). The in vivo BLI assay also suggested that AZA
significantly inhibited the tumor activity in mice compared to PBS (Fig. 3.6b).

Decitabine has been shown to reverse gefitinib resistance caused by DAPK gene
promoter methylation in lung cancer cells, suggesting a role of DNA methylation
in drug resistance and cancer progression (47). Thus, after confirming the
effectiveness of AZA in treating brain metastasis triple negative breast cancer in
vitro and in vivo, we explored the molecular mechanism of action of AZA. EMT is
defined by the loss of epithelial and acquisition of mesenchymal characteristics,
which promotes cancer cell progression, invasion, and metastasis into
surrounding microenvironment (48, 49). Cytokeratins are major structural
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proteins found in epithelial cells, forming the cytoplasmic network of intermediate
filaments (50). As important epithelial makers, the expression of cytokeratins is
decreased during the EMT process, which may contribute to breast cancer
metastasis (27). The human cytokeratin family consists of at least 20 members
coded by different cytokeratin genes including the keratin 18 gene, which is
located on chromosome 12q13 with 3791 bp (28, 51). Keratin 18 plays biological
functions in carcinogenesis and its expression may serve as a differential
diagnostic marker in various cancers such as small cell lung cancer and breast
cancer (52-54). In order to explore role of keratin 18 gene in breast cancer brain
metastasis and hypomethylating agent treatment, we first measured the
expression of the keratin 18 DNA, mRNA and protein. We observed the keratin
18 gene was present in both cell lines (Fig. 3.5b), but its transcription and
translation were dramatically decreased in 231Br cells (Fig. 3.5c and 3.5a).
Moreover, AZA treatment increased the mRNA level of keratin 18 in a dose
dependent manner (Fig. 3.5c). Previous studies have shown that the first intron
of the keratin 18 gene contains GC rich regions with DNA methylation sites,
which are important in regulating its expression (29, 55). Thus, we hypothesized
that the decreased keratin 18 gene expression in 231Br cells is due to DNA
hypermethylation. We sequenced and compared the DNA sequence of intron 1
(737 bp) of the keratin 18 gene between both cell lines and we found the DNA
sequence was identical, further indicating decreased expression of keratin 18 in
231Br cells may due to DNA hypermethylation. Further, we identified three
cytosines that were converted into uracil in 231 cells, suggesting DNA
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methylation status of keratin 18 was different between both cell lines (Fig. 3.5d).
Further HhaI restriction enzyme digestion following PCR analysis confirmed at
least one of the three cytosine sites is methylated in 231Br but not in 231 cells
(Fig. 3.5e). These results strongly suggest that the keratin 18 gene is
hypermethylated in 231Br cells.

So far, two mechanisms of action of hypomethylating agents have been reported:
(i) incorporation of drugs into DNA strands and prevention of RNA synthesis; (ii)
inhibition of the activity of DNMTs which catalyze the process of DNA methylation
(6, 7, 11). Targeting DNA methylation may be the general mechanism of these
agents, however, the precise mechanism of action of hypomethylating agents in
cancer treatment has not been elucidated. DNMTs are enzymes that catalyze the
addition of methyl groups to cytosine residues in DNA. DNMTs found in
mammalian cells include DNMT1, DNMT3a, DNMT3b. DNMT1 and DNMT3b are
found to plays roles in the development of central nervous system while DNMT3a
has important functions in acute myeloid leukemia (56-59). We measured the
expression of DNMT3a and DNMT3b and found the expression of DNMT3a is
only present in 231Br cells while DNMT3b expression is undetectable in either
cell lines. We also noticed that AZA inhibited the DNMT3a expression in 231Br
cells (Fig. 3.5f). The presence of DNMT3a and inhibition of its expression by AZA
in the brain colonizing cells suggests (1) DNA methylation is elevated and (2)
AZA inhibits DNA methylation in these cells. Comparing different methylation
status of the keratin 18 gene between the two cell lines, and the difference in

64

DNMT3a expression provides a correlation and explanation of DNA methylation,
brain metastasis, and effectiveness of AZA in brain colonizing cells.

3.5 Conclusion
In summary, based upon our findings, we believe the DNA hypomethylating
agent AZA may represent as a new class of chemotherapeutic agents and a
novel therapy for treatment of brain metastasis of breast cancer. A recent study
showed that epigenetically reprogrammed genomic methylation serves as a
universal cancer biomarker (58). We propose DNA hypermethylation of the
keratin 18 gene may serve as a biomarker for diagnosis of brain metastasis of
breast cancer, or can be used to evaluate whether breast cancer patients with
brain metastasis are potential candidates and that would benefit from
hypomethylating agent treatment. Moreover, the hypermethylated keratin 18
gene may be a potential drug target that can be used for the development of
novel targeted therapy drugs in treating patients with brain metastasis breast
cancer.
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Fig. 3.1. Brain colonizing breast cancer cells (231Br) have a different
oncological phenotype compared to parental breast cancer 231 cells. (a)
After intracardiac injection, the parental triple negative breast cancer cells (231)
are seen disseminated throughout the body of mice. (b) The brain colonizing
triple negative breast cancer cells (231Br) primarily reside in the brain of mice. (c)
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231Br cells grow significantly faster compared to 231 cells in vitro. Fold change
of cell numbers in each day was compared between the two cell lines using
Student’s t-test. All error bars represent standard deviation (SD), N = 3 technical
replicates, representative of two independent experiments. *p<0.05, **p<0.01,
***p<0.001.

Fig. 3.2. 231Br breast cancer cells are more sensitive to AZA treatment
compared to 231 cells. (a) IC50 values of AZA in both cell lines were calculated
using the MTT assay. The IC50 value of AZA is 48 ± 4.90 M in 231Br cells and
83.33 ± 8.82 M in 231 cells (p<0.01). (b) 231 and 231Br cells were treated with
various concentrations of AZA for 72 hours and the Annexin-V positive cells were
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considered as apoptotic cells. 20 M and 100 M of AZA treatment triggers
higher percentage of apoptotic cells in 231Br cells compared to 231 cells. IC50
values and percentage of Annexin-V positive cells were compared between the
two cell lines using Student’s t-test. All error bars represent standard deviation
(SD), N = 3 technical replicates, representative of three independent
experiments. *p<0.05, **p<0.01, ***p<0.001. (c) Expression of BCL-2 and BCL-xL
in 231 and 231Br cells after AZA treatment for 72 hours measured by Western
blotting assay. Beta-actin was used as the loading control. The blots shown are a
presentation of two independent experiments. (d) Expression of caspase-3 and
caspase-9 in 231 and 231Br cells after AZA treatment for 72 hours. Beta-actin
was used as the loading control. The blots shown are a presentation of two
independent experiments.
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Fig. 3.3. AZA differentially inhibits Wnt signaling transduction pathway and
angiogenesis related markers in vitro. (a) Expression of Wnt-3, Wnt-4, GSK-4,
and beta-catenin in 231 and 231Br cells after AZA treatment for 72 hours
measured by Western blotting assay. GAPDH was used as the loading control.
The blots shown are a presentation of two independent experiments. (b)
Expression of VEGF receptor 2 and HIF-1 alpha in 231 and 231Br cells after AZA
treatment for 72 hours measured by Western blotting assay. GAPDH was used
as the loading control. The blots shown are a presentation of two independent
experiments. (c). VEGF mRNA level in 231 and 231Br cells after AZA treatment
for 72 hours measured by real-time PCR. All error bars represent standard
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deviation (SD), N = 3 technical replicates, representative of two independent
experiments. *p<0.05, **p<0.01, ***p<0.001. (d) The amount of VEGF released
into the cell culture medium of 231 and 231Br cells after 72 hours of AZA
treatment measured by ELSIA. All error bars represent standard deviation (SD),
N = 3 technical replicates, representative of two independent experiments.
*p<0.05, **p<0.01, ***p<0.001.

Fig. 3.4. 231Br cells have higher migration and invasion potential compared
to 231 cells. (a) Quantification of cells migrating across transwells 72 hours
after plating cells in the migration chambers measured by transwell migration
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assay. Y-axis stands for the average number of cell migration per 5 microscope
fields. All error bars represent standard deviation (SD), representative of two
independent experiments. *p<0.05, **p<0.01, ***p<0.001. (b) Quantification of
cells migrating across transwells 96 hours after plating cells in the Matrigel
coated migration chambers measured by transwell invasion assay. Y-axis stands
for the average number of cell migration per 5 microscope fields. All error bars
represent standard deviation (SD), representative of two independent
experiments. *p<0.05, **p<0.01, ***p<0.001. (c) Quantification of cells presented
in the scratch made on day 0 (0 hour time point) at 72 hours after AZA treatment
by wound-healing assay. Cell numbers in the scratch wound were normalized to
0 hour. All error bars represent standard deviation (SD), representative of two
independent experiments. *p<0.05, **p<0.01, ***p<0.001. (d) Expression of
MMP2, MMP9, vimentin, N-cadherin, and pan-cytokeratin in 231 and 231Br cells
after AZA treatment for 72 hours measured by Western blotting assay. GAPDH
was used as the loading control. The blots shown are a presentation of two
independent experiments.
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Fig. 3.5. The keratin 18 gene is hypermethylated in brain colonizing cells
compared to regular breast cancer cells. (a) Expression of keratin 18 in 231
and 231Br cells after AZA treatment for 72 hours measured by Western blotting
assay. GAPDH was used as the loading control. The blots shown are a
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presentation of two independent experiments. (b) Detection of the keratin 18
gene in 231 and 231Br cells after AZA treatment for 72 hours by PCR. The
image shown is a presentation of two independent experiments. (c) Detection of
the mRNA level of keratin 18 gene in 231 and 231Br cells after AZA treatment for
72 hours by real-time PCR. All error bars represent standard deviation (SD), N =
3 technical replicates, representative of two independent experiments. *p<0.05,
**p<0.01, ***p<0.001. (d) Detection and comparison of DNA methylation in the
intron 1 region of keratin 18 gene between 231 and 231Br cells. Bold letters
indicate the intron 1 region of keratin 8 gene. Inserts show the sequencing
chromatogram of bisulfide-converted DNA from 231 and 231Br cell lines.
Sequence in italics shows the HhaI restriction enzyme target site. The DNA
sequencing results represents sequencing five positive colonies generated from
each pair of primers. (e) Digestion of the genomic DNA isolated from 231 or
231Br cells with HhaI restriction enzyme. HhaI primer stands for the use of the
pair of primers to detect the HhaI digestion by PCR (yielding a ~300bp PCR
product if the DNA was not digested by HhaI, and no such a ~300bp PCR
product was formed if the DNA was digested by HhaI). Control primer (“cont” in
figure) is the pair of primers used as positive control to detect the keratin 18 gene
by PCR. The image shown is a presentation of two independent experiments. (f)
Expression of DNMT3a and DNMT3b in 231 and 231Br cells after AZA treatment
for 72 hours measured by Western blotting assay. GAPDH was used as the
loading control. The blots shown are a presentation of two independent
experiments.
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Fig. 3.6. AZA decreases tumor burden and improves survival in mice with
brain metastasis of breast cancer. (a) BLI signal versus time in mice with
treatment beginning on day 21. Each data point represents the mean plus
standard deviation (SD). Mice treated with 2.5mg/kg AZA had significantly lower
tumor burden (p=0.0112). (b) Kaplan-Meier survival plot of mice starting 21 days
after intracardiac injection of 231Br cells. Median survival was 42 days and 50
days, respectively, for vehicle and 2.5mg/kg AZA (p=0.0026).
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Chapter 4
Cannabidiol slows the development of breast cancer brain
metastases.

4.1 Introduction
Brain metastases from distant primary cancers are the most common type of
intracranial mass and typically confer a poor prognosis with limited treatment
options. Once diagnosed, patients commonly survive <2 years on average [1-3].
Of the primary cancers that metastasize to the brain, advanced breast cancer
accounts for roughly 30% of metastatic CNS lesions [4]. Subtype differences
exist, but brain involvement is most common in triple negative and HER2 positive
breast cancers [5-7]. Most treatment options for brain metastases only provide
palliative care and are rarely curative, but include systemic chemotherapy,
radiation therapy, and/or surgical resection if the patient is medically operable [8].
One reason for treatment failure is the blood-brain barrier, which limits the
passive diffusion of chemotherapies and actively effluxes many others. The
blood-tumor barrier in brain lesions is disrupted, or “leak” [9-19]. However, even
in the presence of this leaky vasculature >90% of all metastases failed to reach
cytotoxic concentrations of systemically delivered chemotherapies in a preclinical
model of breast cancer brain metastasis [10, 19]. For this reason, and due to
increased incidence of brain metastasis driven by improved imaging modalities,
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early detection, and enhanced peripheral disease management [20], the
development of novel therapeutic strategies to bypass the BTB is critical.
Cannabidiol (CBD) is a non-psychoactive, non-toxic constituent of Cannabis
Sativa. CBD has been investigated as a potential therapeutic agent in
neurodegenerative diseases, pain, anxiety, depression, cancer nausea,
inflammation, rheumatoid arthritis, infections, inflammatory bowel disease, and
diabetes complications [21-27]. A large body of evidence is being generated in
support of CBD as an anti-cancer agent. The anticancer activity of CBD has been
studied extensively in-vitro. A half maximal inhibitory concentration (IC50) in a
range of 0.67-25µM has been reported in several cancer cell lines [28-30]. Some
potential anticancer mechanisms of CBD have also been reported, i.e., reactive
oxygen species induced endoplasmic reticular stress, inhibition of epidermal
growth factor receptor and insulin growth factor signaling, and downregulation of
ID-1 gene expression [29, 31-33].

In addition to CBD’s favorable therapeutic activity, CBD has desirable
physicochemical properties for brain drug delivery, i.e. a molecular weight of
314.5g/mol, a log P of 6.5, two hydrogen bond donors, and two hydrogen bond
acceptors. Furthermore, CBD distributes to the brain with a partition coefficient
(Kp, brain) of 0.5-4 [34, 35], and is known to inhibit and/or downregulate active
efflux transporters leading to enhanced substrate uptake [36-40]. One strategy
for overcoming active efflux at the BTB is inhibition of ATP binding cassette
proteins, or efflux transporters, such as P-glycoprotein (Pgp; MDR1; ABCB1) and
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breast cancer resistance protein (BCRP; ABCG2) located at the luminal
membranes of the microvasculature within the brain. These efflux transporters
are known to play a role in the protection of the brain from nearly 90% of
pharmaceutical entities. Inhibition of these proteins has been studied both in-vitro
and in-vivo models extensively. Inhibition of efflux transporters by CBD has been
studied in-vitro [37, 41], making it an intriguing concurrent therapy for patients
suffering from BCBM.

In preclinical metastatic breast cancer models, both immune competent and
deficient, CBD significantly decreased breast cancer metastasis to the lungs [30,
33]. In another study, reduced tumor volume was detected in mice treated with
CBD [33]. In preclinical glioma models, CBD and THC potentiated temozolomide
activity and significantly increased the median survival of glioma bearing mice
[44]. In another study, CBD enhanced the radiosensitive of ionizing radiation in
vitro and a combination of THC, CBD and radiation dramatically reduced
intracranially growing glioma [45]. In a recent clinical study, synthetic CBD was
able to extend the survival of glioma and breast cancer patients with reduced
tumor size and/or circulating tumor cells without any undesired off-target effects
[22]. Radiation followed by procarbazine, lomustine, and vincristine (PCV) is a
standard of care for high grade-glioma. In a pilot clinical study, CBD enhanced
the efficacy of radiation + PCV protocol in high-grade glioma patients [42].
Current clinical studies are underway to look at the efficacy of CBD as a single
agent in the treatment of solid tumors [43]. These promising results together with
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CBD’s physicochemical properties prompted us to test its efficacy in breast
cancer brain metastases.

In this study, a half-maximal inhibitory assay was used to determine if CBD is
cable of inhibiting growth and survival of the MDA-MB-231 brain tropic breast
cancer cell line (231Br). The potential for CBD to act as a non-toxic P-gp inhibitor
was evaluated via in-situ brain perfusions. Additionally, CBD was evaluated as a
single agent in the development of metastatic brain lesions. Lastly, mice bearing
231Br metastases were treated with vehicle, CBD, PTX, or a combination of CBD
and PTX to evaluate the impact of CBD alone and in combination with cytotoxic
chemotherapy on tumor burden and overall survival.

4.2 Methods and Materials
Materials
Luciferase transfected brain tropic MDA-MB-231 cells (231Br) were provided by
Dr. Patricia Steeg of the National Cancer Institute (Bethesda, MD). Ketamine and
xylazine were purchased from Patterson Veterinary (Devens, MA). Cannabidiol
was a gift from National Institute on Drug Abuse (Research Triangle Park, NC)
via drug supply program. Dulbecco’s modified eagle medium (DMEM) and fetal
bovine serum (FBS) were purchased from Gibco (Carlsbad, CA). D-luciferin
potassium salt was purchased from PerkinElmer (Waltham, MA). Cell culture
materials and other laboratory supplies were purchased from Fisher Scientific
unless otherwise stated.
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Animals
All experiments involving animals in this work were approved by the West
Virginia University Institutional Animal Care and Use Committee under protocol #
1604001894. Four to six-week-old athymic nude mice or FVB mice were
purchased from Charles River Laboratories (Wilmington, MA) and allowed to
acclimatize for three days prior to use in this study. Mice were kept on a 12-hour
dark/light cycle with ad libitum access to food and water.

Cell Culture
Prior to any experiments, 231Br cells were cultured in DMEM supplemented with
10% FBS and maintained at 37ºC and 5% CO2.

Half-maximal Inhibitory Assay (IC50).
Exponentially growing 231Br cells were seeded at a density of 2000 cells per well
in a 96-well plate. The next day (24hr), cells were treated with increasing
concentrations of CBD ranging from 0.045-100µM. After incubation for 48 or
96hr, 10µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution (5mg/mL) was added to each well. After another 2hr incubation, media
was removed and DMSO was added to dissolve formazan crystals. Cell viability
was detected via absorbance at 570nm on a Biotech Epoch plate reader
(Winooski, VT) (MTT Assay).

In-situ Brain Perfusion
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Mice were anesthetized deeply with ketamine and xylazine (100mg/kg and 810mg/kg respectively). Once unconscious, the thoracic cavity was exposed, the
descending aorta was clamped, the right atrium was nicked and an 18G needle
was inserted into the left ventricle. The mouse was then perfused with a
physiological buffer solution containing 3H-paclitaxel, 14C-sucrose, and/or one of
three inhibitors (PSC833, elacridar, or cannabidiol) at a flow rate of 5mL/min for
three minutes. At the end of the perfusion, the brain was harvested, and the
cerebrum, cerebellum, and brain stem were separated. Tissue was dissolved in
2mL of solvable overnight at 50ºC. The following morning, the samples were
removed and allowed to equilibrate to room temperature. Scintillation fluid, 8mL,
was added and the samples were vortexed. Amounts of 3H-paclitaxel and 14Csucrose in cortical regions and perfusion buffer were quantified using a
PerkinElmer TriCarb 4910 (Waltham, MA). The unidirectional BBB transfer coefficient (Kin) was calculated using equation 4.1 as follows:
𝑄𝑄𝐵𝐵𝐵𝐵

𝐾𝐾𝑖𝑖𝑖𝑖 = 𝐶𝐶

𝑝𝑝𝑝𝑝 ∗𝑇𝑇

(1)

Where QBr is the amount of radiotracer in the brain corrected for vascular
volume, Cpf is the amount of radiotracer in the perfusion fluid, and T is the
perfusion time (180 sec) [44-47].

Breast Cancer Brain Metastasis Progression Model
Athymic female nude mice were randomized into vehicle and cannabidiol groups.
Mice received either vehicle (100µL, PBS:Ethanol:Tween80, 96:2:2) or
cannabidiol (15mg/kg) 5 times per week. After pretreatment for 5 days, 1.75x105
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231Br cells were injected into the left ventricle as described several times by our
laboratory. Tumor growth and cell disposition was monitored twice weekly using
an IVIS Spectrum CT 15 minutes following an intraperitoneal dose of D-luciferin
potassium salt (150mg/kg). Prior to tumor burden analysis, mice were also
weighed. As a surrogate for tumor burden, bioluminescent signal in cranial
regions was measured. On day 32, brains were harvested and subsequently
stored at -80ºC for future analysis.

Cannabidiol Efficacy Study
Athymic female nude mice were injected with 1.75x105 231Br cells through the
left cardiac ventricle. Three weeks later, tumor burden was measured using an
IVIS Spectrum CT as described above. Mice bearing 231Br metastases were
separated into one of four groups Vehicle, CBD (15mg/kg five times weekly i.p.),
PTX (10mg/kg once weekly i.p.), or a combination of CBD and PTX. Mice were
collected when humane endpoints became apparent. Brains were again
harvested and stored as indicated above.

Data Analysis
Nonlinear regression analysis was used for IC50 experiments. A one-way ANOVA
with subsequent Bonferroni’s multiple comparison analysis was used to evaluate
in-situ brain perfusion data. A student’s t-test was used to determine statistical
significance for BLI measurement time points in the prevention studies, and by
one-way ANOVA with additional Bonferroni’s multiple comparison for efficacy
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study BLI measurements. A log-rank (Mantel-Cox) test was used to analyze
median survival data points. All statistical analyses were performed using
GraphPad Prism, version 7.00 (GraphPad Software, La Jolla, CA).

4.3 Results
Cannabidiol inhibits in-vitro 231Br cell growth.
To determine the chrematistics of CBD’s anticancer activity, we first performed
an IC50 analysis using 231 Br cells and MTT assay. CBD’s in vitro IC50 was
13.3µM and 8.5µM at 48h and 96h, respectively (Fig 3.1A). Irrespective of
exposure time, inhibition of cell growth was observed above 1µM.

CBD increases 3H-PTX accumulation during in-situ brain perfusion.
To evaluate the potential of CBD to inhibit P-gp efflux and thereby increase PTX
uptake into the brain, we performed in situ brain perfusions in FVB mice and
compared 3H-PTX brain distribution in the presence of PSC833, elacridar, or
cannabidiol (Fig 4.1B). The unidirectional uptake rates, Kin, for PTX alone or in
the presence of PSC833, elacridar, or cannabidiol were 1.6 ± 0.1 x 10-4, 4.9 ± 0.5
x 10-4, 58.8 ± 10.3 x 10-4, and 57.1 ± 5.8 x 10-4 ml/s/g, respectively. 3H-PTX
uptake was significantly increased in the presence of elacridar and cannabidiol
(p<0.01) but was insignificant in the presence of PSC833. The Kin of 3H-PTX was
also insignificant when comparing uptake in the presence of elacridar or
cannabidiol but was significant (p<0.01) when comparing uptake in the presence
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of cannabidiol or elacridar to that of PSC833. These data suggest CBD can able
to increase the Kin of efflux transporter substrates into the brain.

CBD in the development of breast cancer brain metastasis.
To study the effects of CBD on the development of BCBM, we used an in vivo
mouse model similar to the previous studies. As shown in Fig 4.2A, CBD
treatment significantly prevented the weight loss compared to mice receiving
vehicle treatment (p<0.01). Vehicle treated mice had a maximum weight loss of
12.5 ± 4%, while there was no change in the bodyweight of CBD treated mice.
The bioluminescent signal within a region of interest circumscribing the cranium
was determined in the same mice twice weekly until day 32. Mice treated with
CBD had significantly less tumor burden on day 32 compared to those treated
with vehicle as observed in Fig 4.2B (p<0.05). The maximum fold-change on day
32 for vehicle and CBD treated mice were 14.5 ± 4 and 6.2 ± 1, respectively.
These data suggest CBD may be effective in slowing the development of breast
cancer brain metastases.

CBD and PTX combination failed to increase survival and decrease tumor
burden in a preclinical BCBM model.
To evaluate the efficacy of CBD alone or in combination with PTX, we used our
established breast cancer brain metastasis model. Mice were treated with
vehicle, CBD, PTX, or a combination of CBD and PTX (C+P) once established
brain lesions were observed via BLI on day 21 after inoculation. In all groups, we
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observed that there was no significant difference when comparing BLI intensity
(Fig 4.3). Median survival was 38.5, 40, 38, and 35 days for the vehicle, PTX,
CBD, and C+P groups respectively (Fig 4.3B). Of interest, there was no
significance among any of the groups compared to vehicle treated mice.

Discussion
Despite recent advancements in the management of brain metastases from
primary breast cancer, treatment outcomes and survival remain dismal.
Emerging work indicates that CBD may provide benefits in those suffering from
metastatic cancer or brain tumors [22]. In this work, we observed that CBD had a
slight positive benefit in the development or progression of metastases, as well
as an ability to inhibit P-gp mediate efflux at the BBB through in situ brain
perfusion experiments.

In our first experiments, we set out to determine if CBD was capable of killing
brain tropic cancer cells in vitro. Through an IC50 analysis, we observed an IC50 of
13.3µM and 8.5µM at 48h and 96 hours respectively, suggesting CBD’s
anticancer activity is concentration dependent and time dependent. The
propensity of CBD to induce cell death in multiple cancer cell lines, including
prostate, breast, glioma, colon, and gastric adenocarcinoma are displayed in
Table 1 [28, 48]. Some studies have reported lower IC50 values in a range of
0.67 -3.5 µM [49-51]. However, these studies have used different experimental
protocols such as using serum free media, frequently replenishing the drug
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containing media, or different methods of quantifying cell death. Results vary
depending on the experimental protocol, for example, we have shown that
unbound concentrations and activity of anticancer drugs increase with
decreasing concentrations FBS in the cell culture media [52]. CBD is a lipophilic
molecule (log P of 6.5) with 86-90% plasma protein binding [53], serum free
media will result in 100% of the drug in the unbound state. Lower CBD IC50
values reported in the literature can be explained by the modified experimental
protocols. Literature values using a similar protocol to the one we have used
above confirms the concentration dependent and time dependent anticancer
activity of cannabidiol in 231Br cells (Fig 1A).

To ascertain whether or not CBD could enhance the uptake of substrates that are
subject to efflux by P-gp, we performed in situ brain perfusion experiments in the
absence or presence of CBD and other known inhibitors. Our data suggest CBD
increases the distribution of PTX into brain tissue by up to 37-fold. To our
knowledge, these are the first data set using in situ brain perfusion, though the
uptake of P-gp and BCRP substrates in the presence of CBD has been studied in
vitro, as well as in ex vivo placental studies [37, 39, 54]. An interesting
comparison to our results used the same concentration of CBD (50µM) to
demonstrate the increased uptake of mitoxantrone through inhibition of BCRP in
vitro [39]. Our results in combination with other reports indicate that CBD is
capable of increasing the accumulation of substrates that are subject to active
efflux by either P-gp or BCRP.
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In this work, a dose of 15mg/kg of CBD was used for in vivo experiments.
Previous studies have used 5mg/kg and 15mg/kg in metastatic breast cancer
and glioma models, respectively [28, 31, 55]. Since we are studying breast
cancer metastases that are located within the central nervous system (CNS), we
chose to use the dose reported in glioma studies. Intraperitoneal injections have
been reported to have greater brain CBD concentrations and greater
brain/plasma ratios compared to the oral route of administration, supporting our
choice of administration route [34]. In humans, six weeks of oral administration of
CBD at 10mg/kg/day (~700mg/day) resulted in a mean plasma concentration
between 6 and 11ng/mL (19-35µM ) [56]. The maximum recommended
maintenance dose for Epidiolex is 20 mg/kg/day, according to the FDA’s
allometric dosing calculations, the maximum safe dose for mice translates to
246mg/kg/day [57]. Considering these calculations, our dose falls safely within.
Brain metastatic models have been used to evaluate the impact of potential drug
candidates on the development and/or treatment of breast cancer brain
metastases [58]. After pretreating mice for 5 days prior, and continued 5 times
weekly thereafter, we saw a decrease in the tumor burden in the CBD treated
mice (as suggested by the BLI intensity data, Fig 3A) compared to vehicle
control. In a similar experiment regarding breast cancer metastasis, CBD
(10mg/kg, peritumoral injection) in an orthotopic 4T1 breast cancer model
decreased lung metastasis [29]. Another group reported that CBD (5mg/kg, i.p.)
decreased primary tumor size, as well as the number and size of lung
metastases in a 4T1 model of breast cancer [31]. Our data, for the first time in
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the available literature, suggests that CBD is capable of decreasing breast
cancer brain metastasis raising potential interests in combinational efficacy
studies with other anticancer agents.

In addition, we also evaluated the efficacy of CBD alone and alongside PTX in
our preclinical mouse model of breast cancer brain metastases. We observed
that CBD alone or in combination with chemotherapy failed to slow the
progression or improve overall survival (Fig 3A and 3B). One potential
explanation of these results can be found in previous reports involving inhibition
of efflux transporters at the BBB. While many groups have investigated P-gp and
BCRP inhibition, translation to humans remains poor. It has been suggested that
large increases in CNS penetration are only observed when the percent of BBB
efflux inhibition is high, i.e. greater than 90% [59]. Additionally, the relative
concentration of unbound co-administered agents needs to be less than the Ki or
the concentration at which 50% inhibition of BBB efflux is achieved. Both of these
suggest that the implicated limiting factor for clinical BBB efflux in inhibition is low
unbound plasma levels of the proposed inhibitor [59].

Further supporting this argument is that the pharmacokinetic parameters of CBD
is unlikely to produce an effect. Specifically, CBD is an inhibitor of P-gp [37], but
not its substrate [35]. The minimum concentration of CBD required for P-gp
inhibition is at least 10µM [36, 37]. Given CBD’s low free fraction, 0.1-0.14 [53],
attaining an unbound concentration of 10µM seems unlikely. Given previous
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reports showing that after six weeks of treatment with roughly 700mg/day, a
mean plasma concentration of CBD of 19-35µM was obtained [56]. The
corresponding unbound plasma concentrations is 1.9-3.5µM, which is well below
the desired concentration of efflux inhibition.

Lastly, efflux inhibition depends partly on affinity, Km, of the inhibitor for the
transporter relative to that of the drug substrate for the same transporter.
Knowing these parameters may surely provide insight but fell outside the scope
of this work.

Conclusions
In conclusion, the present investigation confirmed CBD’s concentration
dependent and time dependent anti-cancer activity in 231 Br cell line. CBD was
also demonstrated P-gp inhibition at the BBB and able to increase PTX brain
uptake in in situ brain perfusion studies. Additionally, CBD was able to decrease
the formation of new brain metastases. Lastly, CBD alone and in combination
with PTX was unable to improve survival and reduce burden of established brain
metastases in a preclinical efficacy model of breast cancer brain metastasis.
However, it is important to further explore CBD in different metastatic protocols
due to its favorable brain pharmacokinetic properties and beneficial effects
regarding chemotherapy induced side effects.
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Figure 4.1: Cannabidiol has anticancer activity in the brain tropic MDA-MB231Br cancer cell line and inhibits P-gp at the in-vivo blood-brain barrier.
(A) Half-maximal inhibitory assay demonstrating anti-cancer activity of
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cannabidiol at a concentration of 13.33µM. (B) Paclitaxel uptake is increased
nearly 37-fold in the presence of cannabidiol at a concentration of 50µM in the
physiological perfusion buffer. Data are Mean ± SEM; n= 3-4 per group. Oneway ANOVA followed by Bonferroni’s Multiple Comparison Test. ** = P<0.01
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lost significantly more weight than mice treated with cannabidiol through the
duration of the prevention study. (C) Bioluminescent intensity in mice treated with
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cannabidiol or vehicle. Mice treated with cannabidiol have reduced tumor burden
compared to mice treated with vehicle. Data are mean/SD, n= 10/group,
unpaired t-test on Day 32, **= P<0.01.
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of mice injected with 231Br cells and treated with vehicle, cannabidiol (15mg/kg),
paclitaxel (10mg/kg), or a combination of cannabidiol and paclitaxel.

Cancer Type

Cell line

Prostate cancer

DU-145

Prostate cancer

Exposure

IC50

Reference

72 h

25.3 µM

[48]

LNCaP

72 h

25.0 µM

[48]

Prostate cancer

DU-145

96 h

20.2 µM

[28]

Breast cancer

MCF-7

96 h

8.2 mM

[28]

Breast cancer

MDA-MB-231

96 h

10.6 µM

[28]

Glioma (Rat)

C6

96 h

8.5 µM

[28]

Colorectal

CaCo-2

96 h

7.5 µM

[28]

AGS

96 h

7.5 µM

[28]

Time

carcinoma
Gastric
adenocarcinoma
Table 4.1: Cannabidiol IC50 in various cancer cell lines.
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Chapter 5
Radiation increases BTB permeability in a preclinical model of
breast cancer brain metastasis.

5.1 Introduction
Breast cancer is the most common cancer diagnosis among women in the United
States, affecting nearly one in every eight women, resulting in up to 270,000 new
diagnoses each year [1]. Of these women, up to 30% are at risk for development
of brain metastases during their lifetime [2, 3]. After diagnosis with an intracranial
lesion survival is poor with only one in five women surviving longer than one year
post diagnosis [4]. In triple negative, or basal like, breast cancer (TNBC) up to
30% of women are likely to develop brain metastases at some point in their
lifetime [5, 6]. Treatment typically includes a combination of radiation,
chemotherapy and or surgical resection [7, 8]. In general drugs for TNBC are
limited to cytotoxic chemotherapies, due to the lack of any receptor targets
(estrogen, progesterone, and HER2 receptors) [9].

One reason for the overall treatment failure in patients with brain lesions is the
presence of the blood-brain barrier (BBB) [10-12]. The BBB is an anatomically
unique, physicochemical vascular barrier which forms the interface between
blood system and brain [13, 14]. Under normal physiological conditions the tight
junction sealing of BBB endothelia precludes paracellular passive diffusion of
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most solutes into brain parenchyma. While lipophilic molecules may diffuse
across the cell membranes, and generally do not rely on paracellular diffusion,
active efflux transport pumps, including P-glycoprotein (P-gp, ABCB1), breast
cancer resistance protein (BCRP; ABCG2), and multidrug resistance protein-1
(MRP1; ABCC1) [15-19] actively extrude solutes to the luminal side of the BBB.
In the context of a brain tumor normal components that surround the BBB, such
as astrocytes and neurons are displaced by cancer cells resulting in a leaky
vascular barrier, known as the blood-tumor barrier (BTB). While paracellular
diffusion is generally higher at the BTB, we have shown previously that it is
compromised, the BTB still prevents numerous chemotherapeutics form reaching
cytotoxic concentrations in 90% of all brain metastasis lesions [11].

Current standard of care for brain metastasis of breast cancer usually includes
radiation therapy, which may be delivered differently depending on cancer
progression and patient status. For a single solitary lesion, the tumor will be
resected if operable, and a dose of radiation can be delivered to the resection
cavity by (stereotactic radiosurgery) SRS or postoperatively via whole brain
radiotherapy (WBRT) to reduce the risk of local and regional recurrence. For
patients with a limited number of small intracranial masses (<3cm), SRS can be
used [20]. Some experts suggest the use of additional, or boost, WBRT following
SRS. However, no differences in overall survival have been observed in the data
reported in clinical trials comparing the two modalities [21-25]. The use of SRS
for 5 or more metastases has been investigated as a stand-alone approach or
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with the use of WBRT in addition to SRS [26-28]. The results from this work are
ongoing, but it appears that omitting WBRT may result in increased incidence of
distant brain failure and recurrence. Despite the amount of research conducted
regarding treatments involving radiation therapy, complications such as
neurocognitive decline and local/distant recurrence are unsolved.

While these therapies provide efficacy and may reduce central tumor
progression, it has been reported that it may also increase the permeability of the
BBB [10, 29]. However, the timing and magnitude of the BBB and BTB
permeability changes are not defined well and remain in some debate in the
current literature [10, 29]. Several groups have reported permeability changes
up to 24hrs following radiation therapy, while others suggest that any changes
occur at later time points. Other reports have not been able to document
increases in permeability following radiation treatments [30-38]. Clinically,
neurological effects with radiation-induced BBB permeability changes have been
segregated into two categories – acute (i.e., initial 24hrs), and those described
thereafter, usually weeks to months [39-42].

Based upon the clinical relevance of the therapy, and the relative lack of clarity
regarding the effects of radiation on the BBB, we developed a system for brain
irradiation in a preclinical model of breast cancer brain metastasis using clinical
radiotherapy protocols. Using this model, we quantified the pharmacokinetics of
tracer accumulation across the BBB and BTB in a time and size dependent
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fashion. We observed increased permeability of the BTB at both 8 and 24hrs
following radiation therapy in our immune-compromised preclinical metastasis
model and immune competent model. While there was no BBB disruption in
athymic Nu/Nu mice, we did observe increased permeability in immune
competent mice. This data suggests that radiation increases the permeability of
the BTB and normal BBB with a competent immune system and provides a
platform for the study of the mechanism by which this increased permeability
occurs.

5.2 Methods and Materials
Cell Culture
Brain tropic, human triple negative breast cancer cells, transfected to express
firefly luciferase (MDA-MB-231Br-Luc), were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
MDA-MB-231Br-Luc breast cancer cells were kindly provided by Dr. Patricia
Steeg of the National Cancer Institute of Health, Center for Cancer Research.

Development and Optimization of a Half Brain Irradiation Protocol
To confirm the dose output given by the manufacturer’s commissioning of our
XenX small animal irradiator (Xtrahl, Suwanee, GA) a Farmer® ionization
chamber was placed at a depth of 2cm in a solid water commissioning phantom
setup and irradiated at 220KeV and 13.0mA for one minute for each of the
various conditions required for correction factors as
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outlined in the Task Group

61 protocol released by the American Association of Physicists in Medicine (43).
The dose output at isocenter, with a source to surface distance (SSD) of 33cm
and an open radiation field filtered with a 0.15mm copper filter was 3.62Gy/min.
This dose rate was used as a reference to irradiate a set of EBT3 Gafchromic
calibration films at doses ranging from 1 to 20Gy at a depth of 2cm in the same
solid water phantom setup. These films were utilized to obtain a standard curve
depicting the optical densities of known doses. To determine the dose rate, field
homogeneity, and size of our radiation beam collimated with a 10x10mm
collimator using our custom 3D printed mouse restraint, EBT3 Gafchromic films
were irradiated at 0.5cm depth in solid water with an additional 1cm of solid water
below the film to allow for appropriate buildup and backscatter.

EBT3 Gafchromic Film Analysis
Films were scanned using an Epson (Suwa, Japan) Perfection 4870 flatbed
photo scanner in professional mode without color correction at a resolution of
72dpi. Images were analyzed using the red channel on ImageJ software for all
films. Blank, non-irradiated films were also scanned to minimize background for
each set of films scanned. All films were scanned at least 24hrs following
irradiation exposure [43]. Optical density (OD) was defined as follows [44]:
𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 = 𝑙𝑙𝑙𝑙𝑙𝑙10

𝐼𝐼𝑢𝑢𝑢𝑢𝑢𝑢𝑥𝑥𝑥𝑥
𝐼𝐼𝑒𝑒𝑒𝑒𝑒𝑒

(Equation 5.1).

To determine dose homogeneity in films irradiated using the 10x10mm collimator,
the line function was used to determine the dose at each point along the line. For
each point OD was calculated.
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Histological Confirmation of Dose Deposition and Absolute Positioning
Naïve female FVB mice were irradiated through the right cranial hemisphere with
a single dose of 15.5Gy at dose rate of 2.7Gy/min. Mice receiving a total dose of
15.5Gy in one fraction is similar to the biological effective dose (BED) of mice
receiving a total dose of 30Gy in 10 fractions of 3Gy with an assumed α/β ratio of
10, accounting for the biological effect being mitotic catastrophe and cell death in
MDA-MB-231 breast cancer cells. The equation defining BED can be found
below:
𝐵𝐵𝐵𝐵𝐵𝐵 = 𝑛𝑛𝑛𝑛 [1 +

𝑑𝑑

𝛼𝛼/𝛽𝛽

] (Equation 5.2)

Following treatment mice were anesthetized with ketamine/xylazine (100 and 8
mg/kg respectively) before being transcardially perfused with ice-cold 4% PFA.
Mice were decapitated, brains were harvested and then post-fixed overnight in
4% PFA at 4ºC. Following fixation, brains were then incubated sequentially in
10%, 20%, and 30% sucrose each for 24hrs. Brains were then co-embedded in
15% gelatin matrix, 6 brains per matrix, for bulk sectioning. The gelatin matrix
was then processed sequentially in 4% PFA for 24hrs, 15% Sucrose for 24hrs,
and 30% Sucrose for 48Hrs. The block was then trimmed and placed at -80ºC for
30 minutes. Brains were then sliced in the coronal plane at a thickness of 30µm
on a sliding microtome (HM 450, ThermoFisher Scientific, Waltham, MA)
equipped with a 3x3 freezing stage (BFS-40MPA, Physitemp, Clifton, NJ) at 20ºC. Sections were collected and immuno-stained in 6-well plates containing
0.06% sodium azide in PBS [45].
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Sections were immunostained using a standard free-floating section protocol as
described [45, 46]. Briefly, sections were blocked with PBS, methanol, and 30%
hydrogen peroxide (Fisher Scientific, Pittsburgh, PA) and incubated on a shaker
for 15min. Sections were then washed three times and permeabilized for 30 min
on a shaker with 1.83% lysine (Fisher Scientific, Pittsburgh, PA) in 1% Triton
(Sigma-Aldrich, St. Louis, MO), and 4% heat-inactivated horse serum (SigmaAldrich, St. Louis, MO). Sections were then incubated for 24h with anti-γH2AX
(Ser139; 1-500) primary antibody (Cell Signalling Technology, Boston, MA) at
room temperature, followed by a 2 h incubation with the appropriate secondary
antibody at room temperature.

Metastatic Brain Tumor Model of Breast Cancer
MDA-MB-231Br-Luc cells (1.75 x 105) were injected intracardially into the left
cardiac ventricle and allowed to develop into metastatic brain lesions for 21 days.
Presence of CNS metastases was confirmed by bioluminescent imaging (BLI) on
day 21 using the IVIS Spectrum CT imaging system (PerkinElmer, Waltham,
MA). D-luciferin potassium salt (150mg/kg; PerkinElmer) was administered
intraperitoneally and allowed to circulate for 15 minutes for mice with MDA-MB231Br-Luc metastases before capturing BLI signal. Mice were allowed to
progress until substantial tumor burden was observed as indicated by BLI
intensity (approximately 4 to 5 weeks).

Radiation Treatments
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Mice were irradiated through a single cranial hemisphere, as to provide the
contralateral hemisphere as an internal control for each mouse. Mice received
varying doses ranging from 3 to 30Gy in fractionation and up to 20Gy in a single
fraction. All radiotherapy treatments were delivered at a dose rate of 3.01Gy/min
using a 10mm x 10mm collimator adjusted to target the right hemisphere. At 8
and 24hrs following the final irradiation treatments, mice were collected and brain
tissue was harvested as described above. Mice were euthanized via
exsanguination during the vascular washout period while under deep anesthesia
with ketamine/Xylazine (100mg/kg and 8mg/kg respectively). Brain tissue was
harvested and flash frozen in isopentane (-80ºC) in <60s. Brains were sectioned
and mounted on glass slides and stored at -20ºC until analyzed via fluorescent
microscopy.

Qualitative and Quantitative Fluorescence Imaging
For all image acquisition, an Upright MVX10 Stereomicroscope (Olympus, Center
Valley, PA) equipped with Hamamatsu ORCA Flash4.0 v2 sCMOS camera for
fluorescence imaging, a 2x PlanApo (0.5NA) objective, and a
DAPI/FITC/RFP/Cy5/Cy7 filter set. The GFP (excitation/band λ 470/40nm,
emission/band λ 525/50nm and dichromatic mirror at λ 495nm) filter was used to
acquire images confirming half-brain dose deposition with increased γH2AX
signal. Texas Red accumulation in brain metastases was determined by Texas
Red sum intensity (SI) per unit area of brain lesion using the RFP filter
(excitation/band λ 545/25nm, emission/band λ 605/70nm and dichromatic mirror
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at λ 565nm). CellSens image analysis software was used to analyze images and
quantitate Texas red accumulation. [47, 48]

Data Analysis
Differences in permeability between treated and untreated lesions were
compared using a student T-test (GraphPad® Prism 7.0, San Diego, CA) and
were considered statistically significant at p<0.05.

5.3 RESULTS
EBT3 Gafchromic Film Dose Response
The calibration curve for the Gafchromic Film model used is shown in figure
5.1B, and used as a source of reference for dose delivered in all other film
analyses. The points correspond to the mean ± standard deviation determined by
use of equation 5.1. In the same graph, corresponding error bars are drawn, but
are not visible because they are smaller than the symbols in the figure. The
points were fit with a non-linear regression with an R2 value of 0.9987.
Representative images of irradiated films are shown in figure 5.1C-J. As shown,
the films have a change in color (or optical density) as the dose of radiation
increases.

Half Brain Irradiation Protocol and Histological Verification
It is important to identify the dose rate of each experimental design in case there
are instances of change of dose rate from isocenter under open field conditions.
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To determine the dose output of our experimental design, films were irradiated at
a depth of 2mm in solid water placed on our custom restraint with the Gafchromic
film at isocenter. Images of the film were repeated in triplicate (data not shown).
The irradiated field size was consistent with the intentional square field size of
10mm x 10mm measured with calipers (data not shown). The irradiated field was
in good agreement with predicted doses and demonstrated both horizontal and
vertical beam uniformity as depicted in figure 5.2. A penumbra of ~0.850mm was
observed for this treatment field, as defined by the region where the dose drops
from 80% of the max dose deposited to 20% of the max dose.

To ensure the 10mm x 10mm filed size was accurate and precise for single
hemisphere irradiations, individual radiograms were taken of each individual
mouse alone and then again with the collimator in place. Images were overlayed
using ImageJ at an opacity of 70% as seen in figure 5.3B. Radiograms were
taken under the alignment conditions in figure 5.3A. Our custom 3D printed
mouse restraint ensures the placement of the collimated beam for each mouse
given the lasers are aligned on the outside border of the right eye (y-orientation)
and at the base of the ear (x-orientation) for each mouse. Further confirming
targeting of our in-vivo treatments, anti-γH2AX immunofluorescence was used to
identify regions exposed to radiation. Figure 5.3C demonstrates the ability to
precisely target a single hemisphere in the brain.
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Radiation Therapy Does Not Affect Normal BBB Permeability in Athymic Nu/Nu
Mice.
To understand the effects of radiation therapy on normal BBB integrity in our
preclinical model of breast cancer brain metastasis, mice were irradiated through
the right cranial hemisphere at 3-12Gy in fractionation. Mice were euthanized
24hrs following the last radiation exposure and the brains were collected, sliced,
and analyzed for TxRd accumulation. Compared to untreated hemispheres in
mice that were not exposed to radiation of any dose, no significant increase in
TxRd accumulation was observed at any dose, indicating that the BBB in athymic
Nu/Nu mice retains its integrity 24hrs after radiation therapy (Figure 5.4A-B).
The accumulation of TxRd is reported as sum intensity divided by the area of
interest (mm2) for each area. For mice that did not receive radiation therapy,
TxRd accumulation was 4.12±24 and in mice that received radiation therapy, the
contralateral untreated hemisphere had a value of 4.076±0.045. Mice treated to
at 3, 6, 9, and 12Gy had accumulations of 4.17±0.02, 4.15±0.02, 4.08±0.03, and
4.10±0.01 respectively.

Radiation Therapy Induced BBB Permeability at Low Doses of Radiation Therapy
in Immune Competent Mice.
In some patients the immune system elicits an abscopal affect in some patients
treated with both radiation therapy and immunotherapy leading to synergistic
outcomes. To ascertain the effects of radiation therapy on naïve mice with intact
immune function, female FVB mice were irradiated through the right cranial
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hemisphere at doses from 6-30Gy in fraction identical to the fractionation
schedule that the Nu/Nu strain mice received. Significant disruption of
physiologically normal BBB was observed in mice treated to a total dose of 12Gy
(p<0.05) and, in mice treated to a total dose of 6Gy, an obvious increase was
observed, although it was not significant (Figure 5.4C,D). At higher doses of 18
and 30Gy, there was no statically significant accumulation of TxRd in irradiated
hemispheres compared to the contralateral untreated hemispheres. Means and
standard deviations for the contralateral hemispheres, and hemispheres
receiving 0, 6, 12, 18, and 30Gy were 3.99 ±0.13, 4.08±0.10, 4.21±0.02,
3.88±0.02, and 3.87±0.01, respectively.

Radiation Therapy Disrupts the BTB and Increases Permeability at 8 and 24hrs
Post Insult.
To understand the effect of radiation therapy on the BTB in our preclinical model
of breast cancer brain metastasis, mice were injected with MDA-MB-231Br brain
tropic TNBC cells. After substantial tumor burden was measured (~4-5 weeks)
mice underwent radiation treatments to total doses of 6 and 12Gy. Following
treatment at 8 and 24hrs mice were injected with the small (625Da) passive
permeability tracer TxRd. After a ten minute circulation period mice were
euthanized, brains harvested, and sliced before analysis with a fluorescent
microscope. Tumors in the irradiated regions were compared to contralateral,
untreated hemispheres for total accumulation of TxRd per lesion size, reported in
sum intensity/mm2. For mice receiving 6Gy, untreated tumors at 8 and 24hrs
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following treatment had accumulation of 4.697±0.272 and 4.409±0.284
respectively, while their treated counterparts had total accumulations of
4.846±0.600 and 4.963±0.777 at 8 and 24hrs respectively (Figure 5.5A). For
both time points, treated tumors had statistically significant more accumulation of
TxRd compared to their untreated counterparts (p<0.05). At the 12Gy dose at the
8 hour time point, untreated and treated lesions had values of 4.239±0.192 and
4.389±0.125 respectively. The data was not significant (Figure 5.5B). At 24h
following radiation treatment, values of 4.558±0.379 and 4.798±0.5404 were
determined (Figure 5.5B). Tumors receiving radiation therapy had significantly
more accumulation of TxRd at 24hrs following treatment (p<0.05).
Representative images of an untreated lesion with low permeability to TxRd and
a treated lesions with high permeability to TxRd are shown in Figure 5.5C,D.

5.4 DISCUSSION
Several studies have investigated the effects of radiation on the BBB or BTB, all
reporting different results concerning permeability of brain barriers [49-51].
Additional disparities are observed between reports owing to the non-uniform,
clinically dissimilar dosing schemes. In this study we validate a new experimental
design using the commercially available XenX Small Animal Irradiator and
observed increased BBB permeability to TxRed 24hrs following a total dose of
12Gy in immune competent animals only. Moreover, we also saw increased
permeability of the BTB following low to moderate doses of radiation at 8 and
24hrs following radiation treatment.
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In this work, first we validated our experimental design through small field
radiation dosimetry using a combined ionization chamber and EBT3
Gafchromic® film approach. A similar approach using an equivalent radiation
system has been used previously [52, 53]. Multiple groups have used dose rate
measurements in solid water phantoms, cross calibrated with EBT3 films to
gauge doses delivered for a particular experimental setup [54]. Herein the dose
rate for our small animal irradiator (SAI) at isocenter and an open field was
determined to be 3.62Gy/min, consistent with dose rates for similar field sizes
[52]. The irradiated field demonstrated quality beam uniformity (figure 2) in
comparison with our intended field size and had a penumbra, where dose
deposition falls from 80% of the max dose to 20% of the max dose, measuring
0.850mm. Measurement and outcomes of beam uniformity and field penumbra
for our experimental design are comparable, but vary slightly from others
reporting a beam penumbra of 0.40-0.41mm [55] using a 10x10mm2 field. While
the beam penumbra is critical in small scale irradiation methodology, the intent of
this work was to study the effect of radiation on tumors in a large treatment field
consisting of half of the brain. For this purpose, a beam penumbra of <1mm
would not deliver substantial dose to the region outside the intended field, nor
would it prevent the intended field from receiving a significantly lower dose.

To translate from a dosimetric evaluation of our SAI and its beam characteristics,
we transitioned to an in-vivo system. Using naïve female FVB mice and
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immunostaining, we were able to histologically verify successful irradiation of a
brain hemisphere by increased γH2AX signal in the treated hemisphere (figure
3C). The use of anti-γH2AX staining to ascertain radiation damage, specifically
double stranded DNA breaks, and field sizes in in-vivo systems has been
established [52, 56, 57].

In order to understand the effects of WBRT on the normal brain and brain tumor
vasculature, we modeled clinical dosing patterns to treat and ablate brain
metastases. Patients are commonly prescribed a total dose of 30Gy over 10
fractions [58, 59]. When fractionation schemes are used, it is critical to
understand their translational relevance. One group [60] studied the effects of
fractionated radiotherapy on the BBB and BTB in rats. While the dosimetry was
well executed, the doses and fractionation patterns do not appear to match what
is typically used in patients in the clinic. In a similar study [31], mice were treated
with a single fraction of 10Gy. Interestingly, Zarghami et al. [56] limited doses to
single fractions, but incorporated the use of a BED equation to demonstrate
equivalence to clinical dosing parameters. Of note, changes in fractionation have
shown little impact on tumor progression and survival [59].

However, when examining the effects of a treatment on the blood brain barrier, it
is important to follow clinical parameters and understand the intent of the
treatments. Our experiments were poised to examine the events following a
radiation treatment intended to treat brain tumors. Doses outside of what are
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typically used in patients are not necessarily as translationally plausible as
studies using methods employed in the clinic. Our findings are presented at low
and moderate doses, but were given in the same 3Gy fractions that would be
continued to 30Gy in the clinic.

In non-tumor bearing, healthy female Nu/Nu mice, the BBB was unaffected by
radiation therapy at doses from 0-12Gy in fractions of 3Gy at 24hrs following
treatment (figure 4A). Contrary to our results, Wilson et al [30] demonstrated
increased normal BBB permeability to a 4.4kDa FITC dextran at 24 and 48hrs
following radiation. However, this result was following a single exposure to a
relatively large, 20Gy dose of radiation. Using the BED equation, this equates to
an effective dose that is greater than 1.5 times that of a total dose of 30Gy over
10 fractions [61]. Another study using a single dose of 20Gy that used various
sized FITC dextran molecules observed increased permeability peaking at 24hrs
post-treatment. However, they observed no increases in normal BBB
permeability following a dose of 5Gy, which is much closer to the single fraction
dose we used in our work [37]. The differences in reported measurement of BBB
permeability alterations following radiation therapy can be partially attributed to
the large heterogeneity in the way the dose was delivered, i.e. high dose vs low
dose or single vs multiple fractions.

While our results using athymic nude mice may conflict with reported data,
experiments with mice bearing an intact immune system had a different outcome.
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When immune competent female FVB mice were used in the same experiment,
we observed a significant increase in normal BBB permeability to TxRed 24hrs
following a dose of 12Gy, as well as an increased, albeit not significant,
permeability change 24hrs following a dose of 6Gy (figure 4C). It should be
noted that in the previously discussed experiments, immune-competent rodent
models were used [30, 37]. These results suggest an active role of the peripheral
and CNS immune system in BBB regulation following radiation therapy.
Increased cytokine expression has been observed following treatment with
radiation [62-64]. Specifically, TNFα, IL1β, and IL6 have increased expression,
similar to acute periods after neuro-immunological insults [65, 66]. Additionally, at
a cerebral blood flow rate of 2mL/min/g [67], immune cells traversing the
cerebrovascular network will be exposed to a substantial dose of radiation, more
than likely perturbing an inflammatory response. The damage associated
molecular patterns released and innate immune cell cytokine production following
radiation therapy could potentially amplify this immune response [10, 68, 69]. All
of the underlying inflammatory events following radiation treatments may result in
a potential mechanism for BBB disruption in immune competent subjects.

Lastly we set out to determine the effects of WBRT on the vascular system within
metastatic brain tumors. Our data indicated increased BTB permeability at both 8
and 24hrs following treatment with 6Gy of radiation in 2 fractions, while after
24hrs we saw increased BTB permeability following a dose of 12Gy in 4 fractions
(figure 5). This data is consistent with increased Ktrans values (BBB permeability
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measured clinically) seen in quantitative DCE MRI in irradiated tumors at 24hrs
post-irradiation [70]. Broad beam radiotherapy also displayed increased BTB
permeability in treated lesions [71]. Tumor vasculature response has also been
studied clinically. In 30 patients and 64 total lesions receiving WBRT or SRS,
treatment with radiation increased permeability in initially low leaky tumors [72].
However, in tumors that were already highly permeable, there were no significant
increases in permeability. In opposition to what we have observed in this study,
there have been observations of no permeability changes measured by MRI
gadolinium enhancement [51], though a dose of 20Gy over two fractions was
given. While this is different from our study in terms of single fraction dose and
fraction number, the BED is similar to that of a completed 30Gy in ten fractions.
For a better visualization of how our results align with concluded studies,
pertinent data available in the literature for both preclinical and clinical
experiments are organized in table 1.

One limitation of this study was the time points that were selected for analysis to
determine increased permeability. In the current literature integrity of the BBB
and BTB following radiation treatments

5.5 Conclusions
In summary, this study was able to provide a means of commissioning for our SAI
similar to that detailed by previous work. Additionally we were able to provide a
method for targeted, reliable, and reproducible brain irradiation without the need
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for expensive onboard CT equipment. Finally we evaluated permeability at both
the BBB and the BTB following radiation therapy with doses of clinical
importance. Moving forward, this platform will serve for continued evaluation of
brain barriers and their pathophysiology following irradiation, but also to be used
as a therapeutic tool in preclinical cancer approaches. Moreover, the difference in
normal BBB integrity in different strains of mice with or without an intact immune
systems suggests an abscopal-like response to radiation.
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Figure 5.1. Calibration curve at isocenter generated using WVU HSC’s
Xstrahl Small Animal Irradiator (SAI). (A) Farmer® chamber calibration of
WVU HSC’s SAI. (B) Calibration curve of Gafchromic EBT3 film generated at
isocenter. (C-J) Representative images of film irradiated to doses from 02000cGy.
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Figure 5.2. Dose homogeneity output of a 10x10mm field size irradiated to a
target dose of 5.4Gy. The irradiated 10x10mm field was uniform in both the
horizontal and vertical directions. The penumbra, or the distance between 80%
and 20% of the max dose was determined to be 0.850mm.

Figure 5.3. Histological verification of half-brain irradiation in an in-vivo
system. (A) Representative photographic image of laser alignment on mouse
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providing placement for collimator and (B) dual overlayed radiograms. (C)
Representative image of irradiation of FVB mice with a single dose of 15.5Gy
through the right cranial hemisphere. Nuclei (Blue) were stained with DAPI.
Double stranded DNA breaks (green) are indicated by enhanced γH2AX signal.
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Fig 5.4. The BBB remains intact in athymic Nu/Nu mice but is disrupted at
an intermediate dose in immune competent FVB mice. (A) Athymic nude
mice treated with daily fractions of 3Gy showed no significant difference in
normal BBB permeability to Texas Red at 24 hours following radiotherapy. (B)
Representative image of a Nu/Nu mouse treated with radiotherapy through the
145

right cranial hemisphere. (C) Immune competent FVB mice showed no significant
difference in BBB permeability to Texas Red, except following a total dose of
12Gy given in 4 fractions. (D) Representative image of a FVB mouse treated with
radiotherapy through the right cranial hemisphere.
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Fig 5.5. Permeability of metastatic brain lesions increases in a time and
dose dependent manner following half-brain irradiation. (A) BTB
permeability is significantly increased at both 8 and 24 hours following 6Gy
(p<0.05, n=13) in metastatic tumors in the portion of the brain receiving radiation
treatment. In the mice treated with 12Gy of radiation a significant increase in BTB
permeability to Texas Red was only seen at 24 hours post treatment (p<0.05,
147

n=12-18). (C-D) Representative images of an untreated metastatic brain lesion
and a lesion that was in the radiation field.
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Total Dose Single Fraction Dose
(Gy)
(Gy)
20.0
20.0

a

BED (Gy)
60.0

Preclinical In-vivo Models
Permeability
BTB or BBB
Change
Yes
BBB

5.0

5.0

7.5

No

BBB

12.0

4.0

16.8

Yes

BTB

20.0

10.0

40.0

No

BTB

0.1, 2.0, 10.0

0.1, 2.0, 10.0

0.1, 2.4, 20.0

Yes

BBB

20

20

60.0

Yes

BBB

40.0

2.0

48.0

Yes

BBB

40.0

2.0

48.0

Yes

BBB

6.0
36, 36
10.5
10.5

6.0
4, 6
10.5
10.5

9.6
50.4, 57.6
21.5
21.5

Yes
Yes
No
Yes

BBB
BBB
BBB
BTB

a
b

Mouse/Rat
Immune Status Reference
Strain
C57BL/6J
Competent
30
SpragueCompetent
37
Dawley
BALB/c
Deficient
70
Nu/Nu
Athymic
Deficient
51
Nu/Nu
C57BL/6
Competent
32
SpragueCompetent
76
Dawley
SpragueCompetent
77
Dawley
SpragueCompetent
78
Dawley
Wistar
Competent
73
60
Wistar
Competent
b
Competent
Rats
71
b
Competent
71
Rats

Biological effective dose (BED) was calculated using the parameters given in reference cited, with an assumed α/β ratio of 10.
Strain of rat unmentioned. The F98 glioma model is commonly used in Fisher rats, which are immunocompetent.

Table 5.1. Comparison of dose, BED, and permeability changes among literature reports investigating the BBB
and radiation therapy in preclinical models.
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Total Dose (Gy)

Single Fraction Dose
(Gy)

BED (Gy)

c

Permeability Change

BTB or BBB

Reference

30.0

3.0

39.0

Yes

BTB

72

37.5

2.5

46.9

Yes

BTB

72

10.0, 20.0, 30.0, 40.0

2.0

12.0, 24.0, 36.0, 48.0

Yes

BTB

74a

57.0±7.2

Na

Yes

BBB

75

30Gy

3.0

No

BTB

79

b

Na

b

39.0

a

Doses were in sequential order over the normal treatment schedule. Plasma and CSF samples were taken after each 10Gy segment.

b

Data not given in manuscript.

c

Biological effective dose (BED) was calculated using the parameters given in reference cited, with an assumed α/β ratio of 10.

Table 5.2. Comparison of dose, BED, and permeability changes among literature reports investigating the BBB
and radiation therapy in clinical patients.
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Chapter 6
A Review of Mathematics Determining Solute Uptake at the
Blood–Brain Barrier in Normal and Pathological Conditions
6.1 The Blood–Brain Barrier
The blood–brain barrier (BBB; Figure 1) is the tightly regulated interface of the
brain and its microvascular system composed of endothelial cells (ECs), a
basement membrane, pericytes, astrocytes, neurons, and microglia. Collectively,
these structures cooperate as a highly selective functional barrier capable of
regulating the distribution of molecules to brain parenchyma. Claudins, occludins,
and junction adhesion molecules (JAMs) form an extensive paracellular barrier
between ECs to small molecules, proteins and cells [1]. The ECs at the BBB
also exhibit lower rates of transcytosis as a result of non-fenestrated vessels and
decreased caveolin-mediated vesicle trafficking compared to the peripheral
vascular system [2]. Together, pericytes and ECs secrete an extracellular matrix
that sur-rounds the blood vessels within the brain and forms the basement
membrane in which pericytes and astrocytic end-feet become embedded.
Astrocytes form the outer layer of basement membrane. The basement
membrane serves to facilitate essential intercellular signaling while
simultaneously promoting the selective distribution of molecules into the brain
parenchyma [3]. The unique characteristics of the BBB impart decreased
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permea-bility of solutes in comparison to other vascular networks throughout the
periph-ery.

The primary functions of the BBB are to maintain homeostasis of the brain
microen-vironment and provide neuroprotection. The BBB preserves the brain
microenvironment with influx and efflux transporters. Examples of these include
the OCT1, OCT 2, LAT1, and OAT solute carrier protein transporters, which have
been suggested to facilitate drug influx at the BBB [4, 5],and the P-glycoprotein
efflux transporter, which minimizes the passage of many lipophilic solutes from
reaching the abluminal membrane of the brain capillary network [6].
Dysregulation of the BBB affects cell signaling, immune cell traf-ficking, and
potential neuronal damage [7]. Selective permeability of the BBB is essential for
maintaining central nervous system health, but becomes an obstacle to
therapeutic drug distribution into the brain to treat neurological disorders or
malignancies of the CNS [8].
6.2 Mapping Drug Kinetics at the Blood–Brain Barrier
Mathematical determination of solute permeability rates across the BBB has not
dramatically changed since Patlak et al [9]. described their, at the time, novel
model. In their work, the authors proposed a two-compartment model in which
influx across the BBB is an irreversible, unidirectional process during the
experimental time frame. Model experiments include multiple blood, or plasma,
measurements following an intravenous bolus tracer dose across the duration of
the experimental time frame from the same subject. Tracer concentration in brain
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is also obtained at multiple timepoints assumed to be in the linear range of
uptake for a given tracer. Plotting the ratio of concentration of tracer in brain
(CBr) at time t to concentration of tracer in plasma (Cpl) at time t versus the total
exposure of the animal to a given tracer from time 0 to time t produces a linear
plot as long as the experiment is performed in the range of linear uptake of the
given tracer. Regressing these data produces a line with slope of Kin, or the
unidirectional transfer constant for the tracer used and y intercept representing
the cerebral vascular volume of the test subject measured in units of
volume/time/mass, typically as mL/s/g. The expression for movement of solute
from the brain capillary network and into the extravascular compartments is given
in Equation (1) [9]:

𝑡𝑡

𝐶𝐶𝐵𝐵𝐵𝐵 = 𝐾𝐾𝑖𝑖𝑖𝑖 ∫0 𝐶𝐶𝑝𝑝𝑝𝑝 𝑑𝑑𝑑𝑑 + (𝑉𝑉0 + 𝑉𝑉𝑝𝑝𝑝𝑝 )𝐶𝐶𝑝𝑝𝑝𝑝 (1)

where CBr (tracer/g of brain) is the concentration of tracer in brain, Cpl
(tracer/mL) is the concentration of tracer in plasma, V0 (mL/g) and Vpl (mL/g)
constitute the total tracer concentrations within the brain capillary network, and
Kin (mL/s/g) is the unidirectional transfer constant for a given solute.
To simplify the kinetic expressions and complement the data from the method
above, Takasato and colleagues applied the principles above and created an in
situ brain perfusion technique in which the concentration of tracer in the plasma,
or in this case the perfusion buffer, remains constant. The in situ brain perfusion
technique has several advantages over many traditionally applied barrier integrity
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protocols. The most striking difference that sets the perfusion technique apart
from other methodologies is the ability of the researcher to alter the buffer used
to study active transport, protein binding, and a host of other interesting
interactions at the BBB. Addition of increasing unlabeled substrate in
combination with a constant concentration of radiolabeled substrate can provide
insight to the Michaelis–Menten kinetics for a particular substrate–transporter
relationship [10]. Additionally, adding serum proteins, adding known inhibitors of
efflux transporters [11], or by cooling the perfusion below 37 °C provides the
researchers the ability to study the effects of plasma protein binding [12], the
affinity of a given substrate for a particular efflux transporter [13], and the impact
of temperature [12] on nutrient transport at the BBB. Other notable advantages
include avoidance of extracranial metabolism of the solute of interest, less
extensive animal surgery, and the possibility to study permeability coefficients
over a 104-fold range. The perfusion technique does not replace the intravenous
injection technique, but complements the data obtained. The pharmacokinetic
expression used to determine tracer uptake in the in situ brain perfusion
technique is as follows in equation 2 [14]:

𝑄𝑄𝐵𝐵𝑟𝑟
�𝐶𝐶 = 𝐾𝐾𝑖𝑖𝑖𝑖 𝑇𝑇 + 𝑉𝑉0 (2)
𝑝𝑝𝑝𝑝

where QBr (tracer/g of brain) is the final concentration of solute in the brain, Cpf
(tracer/mL) is the tracer concentration is the perfusion buffer, T (s) is perfusion
time, V0 (mL/g) is the intercept of the vascular marker used in the experiment
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(also known as the vascular volume), and Kin (mL/s/g) is the unidirectional
transfer constant, obtained from the regressed slope of the brain distribution
volume versus time graph.
Data obtained from either of these techniques have been used to make
predictive models to determine how fast a novel or understudied solute may
permeate across the BBB. A handful of physiochemical properties have been
determined to most notably influence BBB permeability: molecular weight,
hydrogen bond donors, total polar surface area, and lipophilicity, or LogP. A good
agreement exists when plotting the literature, or experimentally verified,
permeability coefficients against some variation of the lipophilicity of the same
solute. A variety of mathematical alterations to LogP and the use of
physiochemical properties in combination with LogP have been used to form
predictive estimates of uptake of a multitude of solutes. Figure 2 demonstrates
the relative correlation between LogPS and Log (oil/water partition coefficient ÷
√MW). Using the slope from the linear regressed line and the physiochemical
properties of a novel substrate, a theoretical or predicted permeability coefficient
can be determined.
6.3. Active Efflux at the Blood–Brain Barrier
The BBB dynamically regulates homeostasis and protects the brain from
exposure to endogenous entities, toxic drugs and other xenobiotic substances.
Multidrug transporters present at the luminal surface of the BBB contribute
towards protection by controlling drug distribution and elimination from the brain
by ATP-mediated efflux. A majority of these efflux transporters belong to the ATP
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binding cassette (ABC) superfamily and demonstrate broad affinity for many
clinically used drugs based on structure and chemistry of the molecule. Previous
studies demonstrate differential expression of several types of ABC transporters
at the BBB including P-glycoprotein (P-gp, MDR1, ABCB1), breast cancer
resistance protein (BCRP, ABCG2), multidrug resistance protein (MRP1-6,
ABCC1-6) and the organic anion transporter (OAT3) [13, 15]. Amongst these, the
most clinically relevant ABC transporters implicated in prohibiting drug delivery to
the brain are P-gp and BCRP. These transporters are responsible for limiting
brain access to a wide variety of substrates as a result of extensive expression at
the BBB and blood–cerebrospinal fluid barrier (BCSFB) [16, 17]. Recent studies
demonstrate that these transporters have overlapping affinities for certain
substrates which might lead to higher inhibitory effect to drug permeability as
opposed to that observed for the individual transporters [18].
The kinetics of efflux can be determined using either of two approaches.
Performing in situ brain perfusions as described above to a point of steady state,
or to a point where the ratio of tracer in brain to the quantity of tracer in blood
does not increase further with time, enables the use of Equation (3) [10].

𝑉𝑉𝐵𝐵𝐵𝐵 =

𝐾𝐾𝑖𝑖𝑖𝑖

𝐾𝐾𝑜𝑜𝑜𝑜𝑜𝑜

(3)

where Vbr (mL/g) is the volume of distribution, or the ratio between tracer
quantity in brain and blood, Kin (mL/s/g) is the unidirectional transfer constant
reflecting the rate at which a substance crosses the brain capillary barrier into the
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parenchyma, and Kout (s−1) is the rate of efflux of the same solute. A second
way to measure the efflux constant is to use a modified in situ brain perfusion in
which the brain is preloaded with the solute of interest for a nominal time, and
then perfused with tracer-free perfusate for multiple durations. The
brain/perfusate ratio can then plotted against time. Kout (s−1) can be determined
from these data using the following expression in equation 4 [10]:

𝐾𝐾𝑜𝑜𝑜𝑜𝑜𝑜 = 𝑙𝑙𝑙𝑙2/𝑡𝑡1�

2

(4)

where Kout (s−1) is the rate of solute efflux from the brain capillary system, and
t1/2 is the half-life of linear regressed line on the brain/perfusate ratio versus time
plot. A similar efflux constant can be determined using either expression so long
as the experiments are performed correctly. The in situ brain perfusion technique
is a sensitive, effective method that can be used to determine efflux kinetics as
described above. Previously, the efflux of thiamine at the BBB was determined
using both Equations (3) and (4) [10]. Thiamine efflux did not significantly vary
between different brain regions. Interestingly, using predictive models can
provide an estimate of Kin as described above. When actual measurements of
Kin differ dramatically from predictive models, these compounds are typically
subject to efflux. Additionally, in relation to Figure 2, compounds that are effluxed
at the BBB typically fall below the linear regressed line indicating that something
is preventing them from passing through the BBB as they should based on their
physiochemical properties.
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Bart et al. used the parameter of distribution volume (DV) to quantify the efflux of
P-gp substrate [11C]verapamil [19, 20]. The efflux of radiolabeled verapamil was
measured in rats using PET, and Logan analysis technique was used to calculate
the DV. Logan analysis measures the radioactivity of the analyte drug in the
region of interest, and the DV is calculated as the slope of the Logan plot. MRI
imaging has been used to determine the efflux kinetics after focused ultrasound
induced BBB opening. The efflux was found to drop in the FUS-exposed regions,
and slowly recovered in a time dependent manner [19].

6.4. Flow- vs. Perfusion-Limited Blood–Brain Barrier Transport
Simple diffusion of compounds across the BBB occurs either paracellularly
(between the cells), or transcellularly (through the endothelial cells) [2, 21].
Hydrophilic compounds frequently rely on paracellular diffusion due to their poor
ability to penetrate the lipid bilayer of the endothelial cell membrane. However,
the presence of tight junctions between ECs greatly limits this process. For a
compound to cross into the brain transcellularly, it requires an optimal balance
between lipophilicity and hydrophilicity to cross the lipid bilayers of the cells as
well as the aqueous cytosol. The Lipinski’s ‘Rule of 5′ assists in the prediction of
a compound’s BBB permeability. According to this general rule, compounds with
fewer than 5 H-bond donors, fewer than 10 H-bond acceptors, a molecular
weight less than 500 daltons, and a calculated partition coefficient (logP) value
less than 5 are good candidates for BBB permeability [22-24]. The logP,
determined as the octanol-water partition coefficient of a molecule, denotes its
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lipophilicity. Generally, a direct relation exists between the passive permeability
of a compound across the BBB, and its logP value [25]. This proportionality may
not hold true in the case of hydrophilic compounds that undergo transport
through specific channels, or lipophilic compounds that are subject to active
efflux. Compounds with high lipid solubility can traverse the BBB via simple
diffusion process; their entry into the brain is less limited by their physicochemical
properties, or carrier-based transport. As a result, the limiting step for the entry of
these molecules into the brain is the velocity at which they are supplied to the
BBB interface by the blood. Such compounds are said to have a flow-limited BBB
permeability. Examples of these compounds include ethanol and diazepam. Of
note, these flow-limited compounds are typically used as a measure of cerebral
blood flow. Conversely, as a compound’s logP decreases or becomes more
negative, its lipid partitioning decreases and, therefore, exhibits a reduction in
passive BBB permeability. Their entry into the brain tissue is not dependent on
blood flow, and instead depends on their permeability across the BBB, which is
indirectly dictated by their physicochemical properties. Such compounds are said
to have a permeability limited BBB transport. The transport of solutes occurs over
the entire area of the capillary network, and thus to take the surface area into
account, the product of permeability and surface area is often used to describe
the measure of solute exchange across the BBB, instead of the permeability
coefficient alone [25]. Assuming a unidirectional diffusion of solute, the
concentration of solute extracted from blood flowing through brain capillaries
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correlates with the permeability surface area product using the Renkin–Crone
equation as follows (equation 5):

(5)

𝐸𝐸 = 1 − 𝑒𝑒 −𝑃𝑃𝑃𝑃/𝐹𝐹

where E is the total solute extraction from blood, P is the solute permeability
(cm/s), A is the total capillary surface area (cm2/g of brain), and F is the total
blood flow (cm3/s/g of brain). The above equation can be rearranged solving for
the permeability surface area product, PA (equation 6):

𝑃𝑃𝑃𝑃 = −𝐹𝐹 ln(1 − 𝐸𝐸)

(6)

The unidirectional transfer coefficient, Kin (cm/s/g) can be represented as the
product of solute extraction and blood flow (equation 7).

𝐾𝐾𝑖𝑖𝑖𝑖 = 𝐹𝐹 × 𝐸𝐸

(7)

when the PA values are high (PA/F >> 1), and Kin approaches F, solute entry is
blood flow limited. When the PA values are low (PA/F << 1), and Kin approaches
the permeability surface area product, solute extraction from blood is
independent of blood flow and is considered diffusion limited, as depicted in
Figure 3 [26-29]. The values of PA can range between 10−4 and 10−8 cm/s.
Higher PA values of 10−5 to 10−4 cm/s are observed for solutes with a flow-

160

limited transport such as ethanol, caffeine, antipsychotic drugs, and many CNS
depressants. Diffusion limited hydrophilic solutes, such as sucrose and mannitol,
exhibit PA values several orders of magnitude less, frequently in the ranges of
10−7 and 10−8 cm/s [30].

6.5. Preclinical Measurements of Blood–Brain Barrier Permeability in
Pathological Conditions
Historically, measurements of BBB permeability have been achieved through
multiple methodologies. These approaches include the indicator-diffusion, the
brain uptake index, the concentration profile analysis, the isolated perfused brain,
the intravenous injection, the in situ brain perfusion, and the multiple-time uptake
techniques [13, 14, 29, 31-36]. Each of these methodologies presents its own
limitations ranging from inappropriate assumptions regarding tracer and blood
mixing, to inaccurate estimations of poorly or rapidly penetrating solutes, and
extensive animal surgery [14]. The in situ brain perfusion is capable of estimating
transfer coefficients and evaluating barrier integrity with high fidelity [14, 26, 3741]. However, this technique presents limitations regarding its ability to yield
reproducible results in disease states with a heterogeneous disruption of the BBB
(i.e., brain tumors, stroke, Alzheimer’s disease, etc.). To ascertain these subtle,
variable changes in BBB integrity, the single-uptake approach is widely
recognized as the preferred methodology [36, 42].

161

The unidirectional transfer constant, Kin, in single-uptake experiments following
an intravenous injection of the solute of interest is defined by the relationship in
equation 8 [9, 43-45]:

𝐾𝐾𝑖𝑖𝑖𝑖 =

𝐶𝐶𝑏𝑏𝑏𝑏 (𝜏𝜏)
𝑡𝑡
𝐶𝐶
∫0 𝑏𝑏𝑏𝑏 (𝜏𝜏) 𝑑𝑑𝑑𝑑

(8)

where Cbr is the concentration of tracer contained in the brain compartment of
interest at time T, and Cbl is the concentration of solute in blood. The
denominator of this expression solves for the area under the curve of the change
in plasma concentration from time 0 to time T and indicates total exposure to the
solute through the duration of the experiment. The integral of the plasma
concentration versus time curve is necessary because the concentration of the
test solute in blood changes over time as a result of metabolism and clearance of
the tracer. Cbr is the total concentration of measurable solute that has left the
vascular compartment and distributes to the brain compartment, which is also
expressed as the total quantity in brain as follows (equation 9):

𝐶𝐶𝑡𝑡𝑡𝑡𝑡𝑡 = 𝐶𝐶𝑏𝑏𝑏𝑏 + 𝐶𝐶𝑣𝑣𝑣𝑣𝑣𝑣

(9)

where Ctot is the total concentration of solute in the brain vascular
compartments, and Cvas is the concentration of solute in the vascular space
within the brain. Subtraction of the measured Cvas from Ctot provides a reliable
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estimate of Cbr, or the quantity of tracer distribution into brain for a given period
of circulation time and unit of tissue mass.
While the pharmacokinetic evaluations in this review provide an estimate of the
unidirectional transfer constant for a solute, it has limited insight into the amount
of unbound drug in both the blood and brain at a specific time. When considering
pharmacokinetics of a solute’s transport from blood to brain it is important to
understand that only unbound solute can permeate across the BBB, and the
unbound concentration of solute is what drives pharmacodynamic activities [46].
To determine this, an equilibrium micro-dialysis method is used, where a semipermeable probe is inserted into a specific brain region and perfusate is flowed
through an interior probe and allowed to passively diffuse across the outer
semipermeable membrane. The dialysate is then measured by collection from
the outlet tube [47, 48]. Briefly the equilibrium constant K,p,uu (unbound partition
coefficient) is determined as follows in equation 10:

𝐾𝐾𝑝𝑝,𝑢𝑢𝑢𝑢 =

𝐴𝐴𝐴𝐴𝐴𝐴𝑢𝑢,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝐼𝐼𝐼𝐼𝐼𝐼
𝐴𝐴𝐴𝐴𝐴𝐴𝑢𝑢,𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

(10)

where AUCu,brain and AUCu,plasma represents the total exposure of unbound
drug in brain and plasma, respectively [48, 49]. Determining Kp,uu provides
information on the concentration of drug freely able to act within the brain
parenchyma. This measure accounts for tissue binding affinity and the properties
of active and passive transport across the BBB [50], though it does not directly
measure BBB transport constants. Values of Kp,uu are reported to range from as
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low as 0.02 and 3. Contextually, solutes with high BBB permeability/equilibrium
such as diazepam and oxycodone have a Kp,uu value of 1 and 3, respectively
[51, 52]. Conversely, baclofen and morphine, solutes with poor BBB penetration
and equilibrium, have a reported Kp,uu values of 0.02 and 0.29 respetively [53,
54].
6.6 Clinical BBB PK in Disease States and Preclinical Model Translatability
Measurement of BBB permeability and disruption in humans is not as direct as
preclinical models but is readily achieved with advanced imaging techniques
such as dynamic contrast-enhanced MRI (DCE-MRI), often employed in
oncology and stroke imaging studies [55-58]. This type of imaging provides
researchers and clinicians with estimates of Ktrans to quantify BBB permeability.
As defined by Tofts, Ktrans, with units of min−1 (or time−1), is a volume transfer
constant between blood plasma and extravascular, extracellular space,
predominantly intended for use with tracers that do not readily enter intracellular
compartments (i.e., non-lipophilic tracers) [59]. Measures of Ktrans in DCE-MRI
studies are often calculated utilizing the extended Tofts-Kety (ETK) model, but
can also be estimated from linearized Patlak plots of concentration versus time
data; however, this method assumes negligible backflow of contrast agent from
extravascular spaces into blood vessels during the scanning period [59-62].
Unlike Kin values, Ktrans is expressed in units of time−1 because each
concentration term is based solely on volumetric signal and cannot be
normalized to brain tissue mass, as is the case for preclinical determinations of
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Kin. The ETK and linearized Patlak model equations frequently used in this
setting are displayed below (equations 11 and 12) [59, 60, 63]:

𝑡𝑡

(11)

𝑡𝑡

(12)

𝐶𝐶𝑏𝑏𝑏𝑏 (𝑡𝑡) = 𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ∫0 𝐶𝐶𝑏𝑏𝑏𝑏 (𝜏𝜏) 𝑒𝑒 −𝑘𝑘𝑒𝑒𝑒𝑒(𝑡𝑡−𝜏𝜏) 𝑑𝑑𝑑𝑑 + 𝑓𝑓𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝐶𝐶𝑏𝑏𝑏𝑏 (𝑡𝑡) (ETK Model)
𝐶𝐶𝑏𝑏𝑏𝑏 (𝑡𝑡) = 𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ∫0 𝐶𝐶𝑏𝑏𝑏𝑏 (𝜏𝜏) 𝑑𝑑𝑑𝑑 + 𝑓𝑓𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝐶𝐶𝑏𝑏𝑏𝑏 (𝑡𝑡) (Linearized Patlak Model)

where Cbr is the concentration of contrast agent in the brain compartment, Cbl is
concentration in the blood, fvasc is the volume fraction of vasculature in the
tissue, and kel is the elimination rate constant from brain to blood compartments.
In the linearized Patlak model, the elimination rate constant is ignored as
discussed previously. After pre- and post-contrast infusion scans are obtained,
non-linear (ETK) and linear (Patlak) least squares regression of these parametric
equations are used to estimate Ktrans. The estimates of permeability changes or
barrier disruption provide important clinical implications regarding many disease
states, including cancer and stroke.
Brain tumors, whether primary or metastatic, heterogeneously disrupt local brain
microvascular architecture and function which results in variable increases to
passive permeability of the blood–tumor barrier (BTB) [64, 65]. Notably,
measures of Ktrans in human gliomas are often elevated by orders of magnitude
compared to healthy contralateral brain tissue and has been shown to correlate
with glioma grade [60, 66]. Trends in permeability increases, indicated by foldchanges in Kin values for lesioned versus normal brain are also observed in
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mouse models of glioma and breast cancer brain metastasis [36, 67, 68].
Agreement in trends between the estimates of fold-enhancement indicates that
these mouse models faithfully capture the important underlying factors that
dictate BBB permeability changes observed in humans.
In the case of acute ischemic stroke, clinical studies employing DCE-MRI have
found significant increases in the value of Ktrans in affected regions compared to
normal contralateral areas of brain parenchyma [69]. Elevated fold changes in
Ktrans between affected and unaffected regions (in one study, approximately 3.5
for early post-stroke and approximately 23 for 5–7 day follow-up) [69] are similar
in magnitude to the changes in relative permeability of the BBB to dye observed
in a rat model of ischemic stroke (approximately 15 fold change) [70]. This
indicates that BBB permeability measurements in rodent stroke models
effectively mimic the types of changes in permeability between stroke-affected
and unaffected brain regions in human.
Previously discussed disease states provide validation and justification for the
continued use of mouse and rat models due to their observed pathophysiological
mimicry to clinically observed BBB function in these disease settings. While
absolute values observed in these preclinical models do not scale directly to
clinical values, the observed fold-changes in BBB permeability appear to
translate consistently. Preclinical experiments studying BBB permeability across
various diseases should be designed in light of the importance of appropriate
normal parenchymal controls, as such measures set the baseline for
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determination of clinically translatable and meaningful fold-change
measurements.
Interestingly, the magnitude of fold-change is notably different among preclinical
and clinical determinations of passive permeability. One proposed source of
variance that may be distinct other than the mathematics applied to each model
is the tracer used in each study. Tracer or particle charge, size, polar surface
area, among other properties, all variably affect BBB transport. Keeping in mind
these parameters, a difference in fold-change of 9.2 for TxRed and 47.7 for GdDPTA both in a glioma model may not be all that different given the difference in
physiology of mice and humans, as well as the immune system status in various
animal models. Both provide measures of barrier damage, but also are indicative
of the size, charge, and other chemical properties of that molecule. Figure 4
shows the difference in uptake of three distinct solutes detected through three
separate imaging modalities. The BBB is consistent from species to species, at
least in the case of humans and small rodents regarding cellular makeup and the
rate of uptake of solutes at the BBB. However, what does change among
specifies is the specific transporter composition (i.e., BCRP, P-gp, MRP1, etc.) at
the BBB. While these data may indicate differences among methods, other
correlates of animal and human data can be provided regarding therapeutic
efficacy and brain tumors.
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6.7 Conclusions
The BBB dictates the kinetics of solute transfer into and out of the brain, having
im-plications over the extent of drug distribution and treatment efficacy. This
review outlines the techniques and the mathematical models commonly used to
determine solute influx and efflux across the BBB. These techniques, such as in
situ perfusion and Patlak modeling have found application in preclinical as well
as clinical research. Determination of the rate of drug transfer across the BBB
bears great significance during the preclinical and early stage CNS drug
development process. Application of such methods could help predict drug
disposition, allowing for optimal treatment of CNS pathologies. Further-more, this
review is limited in its capacity, largely describing the unidirectional transfer rate
at which a particular solute crosses the BBB. Not described herein are other
sophis-ticated methods that also aim to determine BBB transport such as the use
of microdialysis and serial CSF sampling. A complex multimodal approach using
a variety of uptake methodology would be suitable for a more complete
understanding of BBB transport for any given solute.
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Figure 6.1. Anatomical differences between (A) blood–brain barrier
vasculature and (B) disrupted vasculature. The BBB is characterized by
presence of endothelial tight junctions, formed by the tight junction proteins and
the adjacent pericytes, microglia and astrocytic foot processes.
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Figure 6.2. Correlation of solute BBB permeability, indicated by its
permeability surface area (PS) product, with the Log(P÷√MW). Compounds
with higher lipophilicity have a greater tendency to traverse the BBB. Compounds
in the green-shaded area are those with values of 80% of reported cerebral blood
flow or high. Compounds in the yellow shaded region indicate those with PS
values between 20 and 80% of cerebral blood flow. Compounds with PS values
in the red-shaded area are those with reported PS values which are less than
20% of cerebral blood flow. Values compiled from literature reported values of
PS [14-17] R2 = 0.78.
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Figure 6.3. A schematic representation of (A) extraction-limited and (B)
flowlimited solute transfer across the BBB. The physicochemical properties of
compounds having extraction-limited permeability are not amenable to BBB
transport. Conversely, the transport of highly permeable solutes across the BBB
is generally quick, and only limited by how rapidly they are presented to the BBB.
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Figure 6.4. Differential tracer uptake in various imaging modalities.
Accumulation of Texas Red 3K (A) and 14C-aminoisobutyric acid (B) in brain
metastases of breast cancer using fluorescent and phosphorescent quantitative
imaging. (C)T1 cortical Turbo Spin Echo MRI indicating gadavist enhancement in
lesions within the brain.
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Chapter 7
Conclusions and Future Directions.
7.1 Conclusions
In conclusion, this dissertation provided a detailed review on the blood-brain
barrier, brain metastases, and treatment strategies to overcome brain barriers
during the management of metastatic and primary brain tumors. Herein, we also
evaluated the efficacy of the hypomethylating agent azacitidine for treatment of
breast cancer brain metastases in a preclinical setting. Additionally, we observed
the effects of radiation therapy on the blood-brain and blood-tumor barriers, as
well as the role cannabidiol plays in active efflux inhibition and in the
management of metastatic brain tumors.

Alteration in the methylation of DNA is used by cells to drive gene expression,
but also by cancer cells to suppress or overexpress different proteins driving
oncogenic progression. Aberrant methylation is found in several cancer types,
include breast cancer. Azacitidine has shown promise in controlling
hematological malignancies, of which many have specific hypermethylated
genes. We found AZA to have a significantly lower half-maximal inhibitory
concentration (IC50) in 231Br cells compared to 231 cells, suggesting that 231Br
cells are more sensitive to AZA due a favorable phenotypic change allowing for
increased brain tropism. AZA was also found to increase proapoptotic and
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decrease antiapoptotic proteins in the 231Br cells. The 231Br cells were found to
have increased hallmark metastasis markers compared to the 231 parent cell
line. The 231Br cells were found to have methylation of the Keratin18 gene,
confirmed by restriction enzyme digestion and correlated with an increased
expression of DNMT3a. This methylation could be targeted by AZA in vivo,
resulting in increased survival and decreased tumor burden.

The non-psychoactive, non-toxic component of Cannabis sativa, cannabidiol, has
shown anecdotal promise in the management of many cancer types, as well as in
the alleviation of chemotherapy induced adverse effects. We found CBD to
induce cancer cell death at an IC50 of ~10μM in the 231Br cell line in vitro.
Additionally, CBD was able to significantly increase the concentration of
paclitaxel, a P-gp substrate, distributing into brain. CBD was found to reduce the
formation of 231Br brain metastases in a prevention model indicated by
statistically less bioluminescent signal accumulation over time. In these, CBD
was also able to help maintain the weight of animals with brain lesions compared
to vehicle treatment. In a combinational approach with paclitaxel, CBD failed to
improve the survival and management of brain metastases. However, results
from this experiment coincide with other literature and clinical results suggesting
P-gp inhibition does not correlate with increased survival. Together, these data
provide evidence of CBD’s potential use in prevention of brain metastases and
the management of chemotherapeutic induced weight decline. Additionally, CBD
has also been shown to inhibit P-gp efflux at the BBB.
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Radiation therapy is a mainstay in the treatment of primary and metastatic
cancers. The impact of radiation on the integrity of the BBB has been
controversial and no defining data has been provided to support either case. In
our work, we developed a rational platform for the use of radiation therapy in both
in vivo and in vitro preclinical models. Using a combination of ionization chamber
and gafchromic dosimetry techniques alongside immunohistochemical
verification, our field was show to effectively deposit radiation doses in vivo with
acceptable field homogeneity. We found the normal BBB to be undisrupted in the
immune deficient athymic nude mouse model at doses up to 12Gy in
fractionation as suggested by Texas Red accumulation. However, in the immune
competent FVB mouse model we found the normal BBB to have increased
permeability 24 hours following dose of 12Gy in 4 fractions. We also noted
increased permeability of triple negative brain metastases treated with 6 and
12Gy to have increased permeability 24 hours following radiation therapy, while
only the lesions treated with 6Gy demonstrated increased permeability of the
BTB at 8 hours following radiotherapy. These data suggest disruption of the BBB
in normal brain tissue following radiation treatment is dependent on immune
system status, further indicating a possible abscopal-like response. Also,
permeability of brain lesions occurs lesions treated with radiation therapy occurs
in a time and dose dependent manner, which may provide for the means to more
appropriately coordinate treatment modalities in patients with metastatic brain
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tumors. The last findings of this work reveal the extensive heterogeneity in the
approach to studying radiation therapy in animal models.

In summary, the work from this dissertation confirms the difficulty in finding a
safe, efficacious treatment for brain metastasis of breast cancer. However, the
hope is that these findings will help push the field forward and provide a starting
point for other researchers to branch from.

7.2 Future Directions
Future studies that are resultant of this work will include the following:

Azacitidine has been shown to impact both survival and tumor burden in our
preclinical models of breast cancer brain metastasis. It been reported that
azacitidine does cross readily cross the BBB. Reduced tumor burden and
increased survival are the main outcomes desired during rationale drug delivery
approaches, but AZA has also been described to have unintended hematological
toxicities. Future studies evaluating the dose of AZA being used should be
performed. The unidirectional transfer constant (Kin) of AZA will also be
assessed using our in situ brain perfusion technique with radiolabeled
AZA.

Literature and anecdotal reports of the use of CBD during cancer treatments
have provided some insight into its potential as a stand-alone or combinatorial
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cancer therapeutic. The data herein indicate that CBD inhibits efflux at the BBB
through in situ brain perfusions. However, in our efficacy study results in
combination with the P-gp substrate paclitaxel did not indicate any modest
increase in survival or decrease in tumor burden. Future studies for this line of
study will include a second set of in situ brain perfusions with the addition
of capillary depletion sub experiments to evaluate the true position
paclitaxel. The results from this experiment will demonstrate whether
accumulation of paclitaxel after P-gp inhibition is truly in the brain parenchyma or
if it is sequestered in the capillaries within the brain. Another future study, will
evaluate the capability of CBD to reduce the neurotoxic adverse effects due
to radiation therapy such as cognitive deficits and glial scarring.

The widespread use of radiation therapy in the management of metastatic and
primary brain tumors requires that we need to better understand the
pathophysiological outcomes of this therapy. The BBB has been shown by some
and by our work to be disrupted following treatment with ionizing radiation. The
extent, magnitude, and time course of this disruption are not well defined.
However, the work herein presents a platform to evaluate these lines of thought.
Also, the immune system plays a clear role in the BBB’s response to radiation
exposure. Future studies will utilize our multimodal fluorescent and
phosphorescent imaging techniques to evaluate the extent and magnitude
of barrier opening at several time points post radiation therapy.
Additionally, the immune cell population and cytokine pool within the brain
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at each of these time points will be evaluated by dedicated flow cytometry
analysis and a MSD inflammatory marker assay. Additionally, using the
applied pharmacokinetics reviewed in Chapter 6, we will quantitatively measure
the unidirectional transfer constant, Kin, following radiation therapy, as well as the
extent to which uptake of nutrients is impacted following treatment.

Novel treatment strategies have progressed the management of primary breast
and other cancers dramatically in recent years. The unintended consequence of
this success in the increase in prevalence of brain metastases. Novel drug
formulations and disruptive methods aimed at bypassing the blood-brain and
blood-tumor barriers provide an optimistic outlook for the treatment of metastatic
brain lesions.

Reframing the aims of my work during my time as a post-doc, I will be focusing
on primary brain tumors, specifically glioblastoma (GBM). Using the techniques
and training, I have received at WVU I will be investigating the impact radiation
therapy has on the blood-tumor barrier in primary GBM, stratified across
biological sex. Lathia and colleagues have observed a more activated microglial
phenotype and decreased survival in female mice deficient in the junctional
adhesion molecule-A. The observed sexual dimorphism that exists is intrinsically
located within a key cellular component of the blood-brain barrier. We will aim to
identify other novel sex differences at the blood-brain and blood-tumor barriers,
but also the extent to which they impact the therapeutic efficacy of radiation
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therapy, and to what extent permeability is increased following treatment with
ionizing radiation.
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